Treatment Considerations
The reduction in estrogen levels associated with menopause is an important contributory factor to bone mineral loss and the development of osteoporosis. Bo ne mi neral density decreases after menopause at a rate of approximately I to 3% per year for 10 to 15 years. The major consequence of this bone loss is an increased susceptibility to fractu re, most common ly o f the vertebrae, hip or wrist. The incidence offraclUre is 2-to 3-fold higher in women than in age-matched men. Hip fract ures are most common in women aged 2: 75 years, with 5 to 20% mortality within the first year. Furthermore, up to 50% of women have significant disability follow ing hip fracture.
The prevalence of osteoporosis and incidence of osteoporotic fracture arc increasing, partly because of increasing l ongevity. Caucasian and Asia n populations arc part ic ularly affected, and other contributing factors include sedentary lifestyle, smoking, alcohol (ethanol) abuse and low dietary calcium intake. In the US, osteoporosis causes more than 1.3 million fractures per year, including 540 000 to 640 000 spine, 200 000 to 250000 hip and 170000 to 200 000 wrist fractures.
Postmenopausal women also lose the protective influence of estrogen on serum lipid profi les and other cardiovascular parameters, causing i ncreased risk of ischaemic heart disease. By the age of 70 years mortality in women due to cardiovascular disease approaches that in the male population.
There are ma ny al ternatives available for the treatment and prevention of both menopausal symptoms and osteoporosis. However, estrogen-based honnone replacement therapy (HRT) is the only option that has proven efficacy in both indications. and that has the additional benefit of reducing cardiovascular risk.
Efficacy, Benefits and Risks
Biochemical markers of bone turnover decrease during HRT, and bone mineral densi tometry indicates prevention of bone loss an d, in some cases, a modest increase in bone mineral density. Concomitant progestogens prevent endometrial hype rpl as ia and do not appear to counteract the beneficial effect of estrogens on plasma lipid profi les if given in low dosages or for long periods. Oral unopposed estrogens decrease plasma levels of total cholesterol and low density lipoprotein (LOL) cholesterol and increase high densi ty lipoprotein (HOL) cholesterol. Smaller improvements in serum lipid profiles have been observed with transdennal preparations, which have also been noted to reduce triglyceride levels. Estrogen also has an antioxidant effect on LOL. and reduces lipoprotein(a) levels when administered concomitanliy wi th p r ogestogens.
Alt hough most clinical trials report increased bone density with HRT, evidence for the prevention of fracture is conflicting. It appears that sustained HRT for 2: 5 to 10 years may be necessary to significantly reduce the incide nce of osteoporotic frac ture. I nt erestingly, a trial in postmenopausal women with previous osteoporotic fracture indicated that HRT may also reduce refracture rates. Furthermore, progestogens given concomitantly may enhance the bone-conserving effects of estrogens. Prolonged HRT is necessary for most beneficial effects but long t erm compliance with HRT may be as low as 30%.
A range of assumptions concerning the benefits and r i sks of HRT have been used in economic evaluations. Relative ris k of osteoporotic fracture was assumed to decrease to a minimum of 0.5 with prolonged therapy. Similarly, relative risk of cardiovascular mortality was assumed to decrease to 0.5, although some studies assumed that the addition of progestogens would halve the PharmacoEco1lomics 5 (6) 1994 protective effect. The reduction in the relat ive risk of cerebrovascular disease was estimated to be between 0.75 and l.O, dependi ng on the duration of therapy. Increased risk of endometrial cancer was assumed to vary between 1.0 (f or combined estrogen an d progestogen therapy) and a maximum relative risk of 8.0 for long lenn unopposed eSlrogen therapy. Most pharmacoeconomic studies used an increased relative risk of 1.25 to 1.5 for breast cancer.
Data concerning alterations in quality of life with HRT are limited. Hip fracture has been assumed 10 reduce quality of life with utility val ues between 0.95 10 0,36, depending upon the outcome and level of disability induced by the fracture.
Pharmacoeconomic Considerations
Hospitalisation costs form the majority of the total costs of hip fracture, which is the most expensive osteoporotic fracture to treat. [n the UK, hip fracture treatment cost £5606 per episode in 1992. and the combined cost of all episodes has been estimated to account for approximately 1 % of the National Health Service total budget. Estimations of treatment costs for hip fracture in the US ranged from SUS 10 250 to $US4l 723 per episode in 1987/1988 . depending on the cost components included. Venebral fractures are assumed to cost between 25 and 45% of hip fracture costs per episode. although some investigators assumed that only 50% of venebral fractures would require treatment. In the UK direct hospitalisation costs for venebra[ fracture account for approximately I to 2% of such costs for all osteoporotic fractures.
Cost-benefit studies of HRT in the prevention of osteoporotic fracture used various methodologies and are therefore not directly comparable. One US study included indirect costs and evaluated the cost benefit of screening White women with bone mineral absorptiometry before initiating a IS-year course of HRT. With compliance assumed to be 90% in women at high risk of fracture, and 70% in women at moderate risk of frac ture. cost savings were estimated to be $US5.1 million in a cohan of 100 000 women over a period of 40 years.
Cost-effectiveness and cost-utility study outcomes have in pan concurred with the strategy of selective treatment of women, but most have not included compliance data. Cost-effectiveness results are most favourable for HRT in women with hysterectomy, a high risk of osteoporotic fracture, and receiving long term therapy. Funhermore, HRT is most cost effective when a reduction in cardiovascular risk is assumed. Screening and HRT for asymptomatic women in the high· risk group (bone mineral density < 0.9 glcm 2 ) cost SUS 11 700 per year of life saved (YLS), compared with $US68 900 per YLS for universal treatment in a hypothetical model. Utility outcomes emphasise the imponance of menopausal symptoms in improving cost effectiveness.
Drug and monitoring costs we re a s t rong influence on the cost effectiveness of HRT in prevention of osteoporotic fracture. Sensitivity analyses also identified the prevention of cardiovas· cular disease as a major determinant of cost effectiveness. Quality-of-life changes due to hip fraclUre sequelae were considerable, reducing incremental cost-effectiveness rat ios by approximately 60%. In all instances, long term HRT was more cost effective than shan term therapy, and in general. the cost per quali ty-adjusted life year (QALY) with HRT was comparable with those for other health interventions relevant to the older adult population.
The economic consequences of menopause are a major concem for healthcare systems in every industrialised coun try. Epidem iological data indicate that morbidity and mortality due 10 osteoporo tic fracture are escalating worldwide, and women are panicularly at risk because of menopause-related physiological changes (Avioli 1988 ). I n addition. cardiovascular disease is a l eading cause of death in postmenopausal women, and this is in part due to the reduced cardioprotective influence of estrogen as estrogen levels decli ne fo llow ing the cl imacteric. T hi s review evaluates the pharmacoeconomic considerations associated with the use of estrogen-based honnone replacement therapy (HRT) as prophylaxis for the longer term consequences of the decline in estrogen levels associated with menopause , i nclud ing osteoporosis and changes in cardiovascular risk factors . HRT in women ex~ periencing menopausal symptoms, as well as those symptoms associated with urogeni ta l estrogen deficiency (i.e. the early and mid-term effects of the decline in estrogen levels) were evaluated in Part I of this review (Whittington & Fau lds 1994).1
Long Term Effects of
Estrogen D e ficien cy
Osteoporosis
One of the most important pharmacoeconomic impl ications of menopause to society is the i ncreased ri sk of bone frac ture resu lti ng from the loss of bone mi neral content ( fig. I ). The mortality rate in women from osteoporotic fract ure is gr eater than the combined mortality rates from cancers of the uterus, cervix and breast (rev iewed in Avioli 1988) . In 1988, total costs of hip fract ures were est imated to be $US8 700 million in the USA (including direct and indirect costs) and £160 million (direct hospitali sation costs on ly) in the UK (r eviewed in Melton 1993) .
Epidemiology
Both the prevalence of osteoporosis and the incidence of osteoporotic fracture appear to be increasing. The i ncidence of hip fracture increased by 28% between 1977 28% between and 1982 28% between in Belgium, by 109% between 1965 and 1 983 in Sweden and b y 40% between 1970 and 1 980 i n the US . Similar trends have been reported in Canada, Norway, Italy, Spain and the U K (reviewed in Avioli 1988) . I n t he US, osteoporosis causes more t han 1.3 mi ll ion fractures per year, including 540 000 to 640 000 spine, 200 000 to 250000 hip and 170 000 to 200000 wrist fractures (Po lan 1994 (Cooper et al. 1992) . These invesligators suggested that the total n umber of hip fractures occurring in the world each year will ri se from 1.66 mil lion in 1990, to 6.26 million in 2050. Although hip fracture incidence rates are expected to decl ine i n Europe and North America, steep increases are expected in A sia and Latin America due to a disproportionate rise in the elderly popu lation (Cooper et al. 1992; Melton 1993) . The risk of fracture is gr eatest in the e l derly, and Caucasian and Asian populations have a higher risk than Blacks (Avioli 1988 ) . However, current increases in t he incidence of hip fracture exceed those predicted by increased longevity, which accounts for only about 60% of the increment observed in Sweden, the US and the U K (Avioli 1988) . Other fac tors that increase risk include smoki ng, alcohol abuse, sedentary lifestyle and low calciu m intake (table I) . Rheumatoid an hrilis causes an increase in bone loss that can be aggravated b y t he use of corticosteroids, mak.ing this patient p opu la-lion highly susceptible to osteoporotic fractu re ( r eviewed in Adachi ct al. 1993; Olbrich! & Benker 1993) . Thyroid hormone use al so causes a significant decrease in bone mineral density in elderly women (Schneidercl al. 1994) . although no studies 10 dale have shown an increased risk of fracture in th is patient group (Cooper 1994) .
Women are at a greater fisk of osteoporosis than men, as they have less bone al all ages. In addition. women experience a sharp acceleration ofbonc loss during the 5 years following menopause, with the greatest losses occurring in the first 2 years. The incidence of fracture is 2-or 3-fold higher in women than in age-matched men. Of women aged 60 and 80 years, 7 and 25%, respectively, have sustained a fracture of the forearm, vertebral body or femoral neck, compared with 3 and 8% of men. Other studies s uggest that 25% of women in their sixth decade will sustai n an osteoporos is-related fra ctu re, and that thi s percentage will have doubled by the age of70 years (rev iewed in Francis & Sutcliffe 1990) .
In a large study that followed 9700 women for 0.8 to 2.8 (mean 1.6) years, 53 women (mean age 75.5 years) sustained a fract ure of the proximal femur (Cummings et aI. I 990a) . Age and reduction in bone mass were independently associaled with an increased risk of hip fractu re, and the risk of hip fracture doubled with each 10 years of age. The risk of fa ll ing also increases with age, although only a small minority of falls result in fracture (Cummings et al. 1990a ). In addition, in individuals aged 2: 50 years women fell 4 times more often than men (reviewed in Griffin (990) . Menopause results in a decline in muscle strength in women, which may contribute to the increase in falls as women grow older (Phillips e t al. 1993 ).
1.J.2 Costs of Osteoporotic Fracture
Osteoporotic fractures in the e lderly constitute a major healthcare problem, both socially and economically. Costs to the Australian national health system pertaining to osteoporosis have been estimated as more than $A250 million annually (Lowthian \993). However, the methods used to identify these costs were not stated. In Argentina, annual PharmacoEconomics 5 (6) 1994 private expenditure on osteoporos is in postmenopausal women was estimated as $US293 176400; annu al public expenditure was estimated 10 be SUS 103968800 with both esti mates based on prescription surveys, drug costs and physician visits in 199 1 US dollars (Tieffenberg 1993a,b) . Other economic analyses have considered vertebral, wrist and hip fractures separately; and a lthough the standard treatment and therefore costing is different in each country, some trends are ev ident.
Vertebral Fracture Vertebral fracture s, although causing pain and loss of height, tend to require a relatively small proportion of heahhcare resou rces, as hospitalisation (if required) is generally brief. Direct hospital costs for vertebral frac tures were estimated at £2 to £3 mi llion per year in the UK (England and Wales) in 1991 , approximately 1 to 2% of direct costs due to all osteoporotic fractures (Kanis & McCloskey 1992) . These investigators calcu lated that outpatient attendance and fracture assessment wou ld add a further £ 10 mill ion annuall y to direct cost estimates, Similarly, lreatment for spinal microfractures in Argentina was estimated to cost $US2 032 519 in 1991, 1.9% of total costs for osteoporotic frac tures (Tieffenberg 1993a) , Costs were calculated for only one-third of the total fracture incidence and i ncluded physical therapy and the cost of a brace for 10% of patients, Clark and Schuttinga (1992) estimated that direct and indirect costs wou ld range fro m $US8723 to $US9917 (1988 dollars) per vertebral fracture, dependi ng on patient age, It was assumed that on ly 50% of fractures would require treatment, and no costs were assumed for the remaining 50%, The duration of hospitalisati on and the average national costs were based on publi shed studies and government statistical data, but details of casted items were not stated, The total cost per vertebral fractu re was approximately 25% of the estimated cost of a hip fracture, In contrast, Rovira and Trinxet ( 1993) provided detail s of direct costs of vertebral fr actures in a Span ish setting (table 11) , and estimated that the total cost per fract ure was Pta4l5 125 (1989 pesetas), approximately 45% of the cost of a femora l neck frac ture, It was not stated how these costs were derived, but it was assumed that all vertebral fractures would requi re treatment.
Wrist Fracture Wrist fract ures were usually assumed to be treated on an outpatient basi s, and costs typically included 519 a number of follow-up visits, The most detailed cost analysis was provided by Rovira and Tri nxet (1993) [table II I for treatment in Spain; in comparison, US investigators assumed a IOtal cost of $US250 per wrist fracture (1982 dollars) but did not detail cost components (Weinstein & Schiff 1983) , Costs in Australia for a consultation, closed reduction and serial x-rays were estimated as $A439.50 per wrist fractu re in 1988 (Cheung & Wren 1992) , and in the UK treatment for a wrist fracture was assumed to include 3 outpatient visits, each of which cost £36.89 at I 989fl 990 prices (Daly e t al. 1992 ). Tieffenberg (1993a) incl uded physical therapy fo r 50% of Argentinian patients in their cost analysis, giving a total direct cost estimate of$US 127 per wrist fracture in 199 1.
Hip Fracture Hip fractures are the most serious type of osteoporotic fractu re, with 5 to 20% of patients dying wi thin 1 year of inj ury, and over 50% of the survivors be ing incapaci tated. The cost of hip fracture in the UK has been estimated as 1 % of the total National Health Service budget. with the direct hospital costs in 1988 estimated to be £160 mi llion (r eviewed in Griffin 1990 ). In the UK, 20% of orthopaedic beds in 1992 were occupied by elderly patients with a f r actured neck of femur, and 20% of these had a fatal outcome (Palfennan 1993) , Pharmacoeconomic studies have used case-fatality rates of 10% (Roche & Vessey 1990 ; Wei nstein 5 (6) 1994 costs are taken into account. Clark and Schuttinga (1992) estimated the cost of lost productivity and housekeeping associated with hip fracture. In women aged 50 to 54 years. lost earnings due to hospilalisation and recuperation increased the cost of hip fracture to $U54 1 723. compared with $U537 968 in women aged> 85 years.
Thu s. in terms of mortality and cost. hip fractures are of g reater significance than either vertebral or wrist fractures. Nonetheless. wrist and vertebral fractures also add an important cost to society. Compston (1992) suggested that vertebral fractures were likely to cause the greatest degree of morbidity. as they occur at a younger age than hip fractures and can result in pain. deformity and disability for many years. Additionally, the loss of nonnal hand movement due to immobilisation of a wrist fracture may make a considerable difference to independent living. and may have a significant effect on quality of life. Further research is clearly warranted to quantify these effects.
Ischaemic Vascular Disease
Ischaem ic heart disease is the most common cause of death in both men and women in the developed world. but premenopausal women have inherent protection compared with their male counterparts that appears to be mediated by estrogens (Ross et a l. 1990) . Estrogen deprivation produces a lteration s in lipid metabolism, resu lting in increased plasma levels oftriglycerides.low density lipoprotein (LDL) and total cholesterol. and decreased levels of high density lipoprotein (HDL) cholesterol (Jensen 1992) . In addition. estrogen may be cardioprotective by favourably modifying coro nary vasoreactivity (Reis et al. 1994) . The cardiovascular risk in women gradually increases arter menopause, and women and men have similar rates of cardiovascular disease by age 70 years (Ross el al. 1990 ). Many factors are implicated in the development of ischaemic heart disease. and the influence that estrogen deficiency may have is dirricult to determine. However. there is lillie evidence that menopause induces changes in blood pressure. body- weight. ci garette smoking or glucose tolerance (reviewed in Jensen 1992) .
Estimates of the costs associated with ischaemic disease have been made using a variety of methods. Costs of myocardial infarction including sudden death were estimated in Australia as $A5214 per epi sode in 1988 (Cheung & Wren 1992) . A study based in the UK assumed thai each hospital admission cost £1200 for ischaemic heart disease and £6500 for treatment of stroke (year not stated) Vessey 1990}. Rovira and Trinxet (1993) estimated that direct costs (including related costs of resources and services f or the 5 years following the episode), were Pta421 183 for acute myocardial infarction. Pta604 605 for cerebrovascular accident and Pta556 862 for other ischaemic disease ( 1989 Spanish pesetas). Tieffenberg (1993a.b) esti mated the total public and private expenditure in Argentina for the treatment of stroke in postmenopausal women who did not receive HRT as $US287 007 376 per year. Thi s estimate was based on the Argentina Social and Health Ass istance Programme for the Elderly (PAM I) module hospitali sation costs, and which included hospitalisation, nursing costs, drugs, computerised tomography and routine laboratory studies, as well as 6 months of in-and outpatient rehabilitation.
Prevention and Treatment of Osteoporosis
Improvement in dietary calcium intake. an increase in the l eve l of exercise. and measures to prevent fall s are generally considered the first steps in a programme designed to prevent osteoporotic fracture (Eden 1993; Griffin 1990 ). This adv ice should be considered mandatory for all perimenopausal women, as improved public awareness of preventative measures may have a substantial effect o n the financial burden of osteoporosis on society. An increased intake of plant estrogens and vitamin 0 in the diet may also be useful (reviewed in Vines 1993) . In addition, other behaviour modification (for example, cessation of smoking) may prove va luable in reducing both osteoporosis and cardiovascular disease. For most Pharmaco Economics 5 (6) 1994 women it is likely, however, that these measures alone will be insufficient to prevent osteoporosis for the duration of their postmenopausal lifespan. Indeed. there are no direct data to suppon the proposal that an increase in exercise prevents fracture (although increased bone density with exercise training is well established), and the efficacy of calcium supplementation in the immediate postmenopausal period remains controversial (Fioretti et at 1991; Prince et al. 199 1: reviewed in Reid 1994) . Additional strategies are normally required and these are briefly discussed in the following sections.
Screening Procedures
As a large proportion of the female population is at risk of osteoporotic fracture, s imple, effective and inexpensive methods of idenlifying those women most likely to benefit fr om HRT may be a critical componenl of the overall cost of prevention. Although the risk facto rs outlined in table I are clearly established, there is lillie ev idence to suggest that these can be directly applied to determine individual therapy requirements. Indeed. there is no sign ificant correlation between the presence of ri sk factors and bone mass at menopause (reviewed in Johnston et al. 1989; Melton et al. 1990 : Slemenda et al. 1990 ).
Other inexpensive approaches have also been explored with more promising results. The severity of climacteric sy mptoms may be useful in determining the requirement for HRT. A 2-yearcomparative study of women with climacteric sy mptoms receiving HRT, and individually-matched untreated women, indicated that the degree of sweating reported was independently associated with the rate of bone loss (Naessen et al. 1992) .
Rouline x-ray is not considered useful because bone loss must reach approximately 30% before changes are evident. and by this stage the first fracture has usually occurred (Eden 1993; Polan 1994) . Biochemical markers of bone loss (e.g. urinary excretion of calcium and hydroxyproli ne, serum levels of calcium. phosphate, alkaline phosphatase, osteocalcin and intact parathyroid hormone) have also been used to provide evidence of bone turn-over rate (Balfour & McTavish 1 992) . A 1 2-year prospective study indicated that a single biochemical screening o f bone turnover rate combined with bone mass measurement identified those women at highest risk of Co lies' or vertebral frac ture ( Hansen et al. 1991) . However. thi s method may be troublesome for the pati ent . who is requ ired to fas t overnight, collect urine specimens. and undergo venepuncture. Other biochemical markers of bone loss such a s pyridinium crosslinks may prove more useful in future . as no dietary restrictions are r equired, and the t est on ly requires a urine sample (Hassager et al. 1 992: Seibel et al. 1993; Uebelhart etaI.1991) .
At present, assess ments of bone mineral density appear to prov ide the m ost accurate. reproducible means of stratifying patients according to their ri sk of fracture (reviewed in Melton et al. 1990 : Purdie 1992 . The development of noninvasive techniques fo r accurate measureme nt of bone mineral density has provided a breakthrough in the study of bone loss and the effects of various treatment modalities. Methods which are common ly used i nclude dual or single photon absorptiometry. dual energy x-ray absorptiometry and quantitative computerised tomography. The choice of measurement site is important because of the varying proportions of trabecular and cortical bone throughout the skeleton. Since trabecu lar bone is more sensitive than cortical bone to alterations in bone resorption. measurements made at different sites may vary considerably (Ni las & Chri stiansen 1989).
1990 charges for single photon absorptiometry in the US ranged between $US35 and SUS 120 per scan, whereas dual photon absorptiometry scanning charges usually exceeded $USlOO. In the same study, charges for quantitative compu terised tomography ranged from SUSlOO to $US400 (Melton et al. 1990 ). In cost-effectiveness studies. the cost of screening for osteoporosis by bone densitometry in the US fo r a cohort of 100 000 women was estimated to be SUS 15 million . or SUS I SO per screen ing in 1987 (Tosteson el al. 1990 ) and 1988 val ues (Clark & Schuttinga 1992) . Costs in the UK in 1989 were estimated as £50 per single photon 523 absorptiometry per scan. £80 per single si te scan using dual phOlon absorptiometry or dual x-ray, and £1 00 to £150 per computerised t omography (Griffin 1990 ). The capital cost of a dual energy x-ray absorptiometry machine was approximately £50000 in 1992. and it has a useful life of about 7 years. Running costs of a screening programme (including operators. maintenance and administration) with th is device were estimated to be between £45000 and £50 000 per year (Anon. 1992). Mass screening in the UK was presumed to reduce costs per measurement by approx imately 50% ( Griffin 1990 ).
Therapeutic Options
Agents which prevent bone resorption have proved mos t s uccessfu l to date. but bone loss prior to therapy is only partiall y r eplaced. This implies that the most efficient time to ini tiate therapy with antiresorptive agents is at the cli macteric. The comparative effi cacy of these agents has been discussed in several reviews (Avouac 1993; Kani s 1993 : Noyes & Dem mler 1990 : Recker 1993 , and only a brief summary is pr esented her e.
There are many treatment opti ons available for the prevention and treatment of osteoporosis including calcium. estrogen. calcitonin. calcitriol. bisphosphonates. fluoride . and other agents such as anabolic steroids. strontium . ipriflavone and parathyroid hormone. Results of clinical studies may be open 10 interpretation because of poor study design and the possibility thm some end-poi nts (e.g. vertebral fr acture) are difficult to quantify (Kanis 1993) . In addition, restoration of bone mass may not reduce the risk of fracture to that in premenopausal women. as the structural weaknesses in bone architecture may remain. Notwithstanding this, any delay in bone l oss is likely to reduce the risk of fracture .
Prefe rred treatment regimens for the prevention of osteoporosis differ between countries. Calcium supplementation is available in most countries and is often administered with calcitoni n, calcitriol or fluoride. Typically. calcium carbonate I glday is prescribed. although calcium supplementation i s also avai lable as calc ium l actate, calcium citrate and calcium gluconate. In the US, average wholesale price (AWP) for various calcium fo rmu lati ons in 1990 varied between $US 1.1 0 a nd $US50.03 for 1 month of treatment. In genera!, calcium carbonate preparalions were the least expensive therapeutic option (Noyes & Demm ler 1990) .
Calc itonin was the most prescribed d rug in terms of Ital ian National Health Service (N HS) expenditure in 199 1. An analys is in Northe rn Italy indicated an expendi ture of £13 million in 6 months (5% of NHS drug costs), with most prescribed for pat ients aged;:: 70 years. In contrast, HRT was prescribed much less frequentl y, and main ly i n women aged 50 to 60 years (Magrin i el al. 1992) .
Calcitonin and calcitriol are approved treatments for osteoporosis in the US. Europe a nd Japan, b ut HRT is generally considered the preventative therapy of choice in France, the US and the UK. Calcitonin, etidronic ac id (etidronate) and fl uoride are used in France as curative therapy fo r osteoporosis (Avouac 1993) . Acquisition costs of these agents are relatively high compared with calc iu m suppleme ntation, with 1993 costs (based o n AWP) per month of treatme nt approximating £240 for calcitonin and £60 for calci triol. compared with £1.50 for calcium carbonate (British National Form ulary 1993) .
Fluoride therapy is an approved treatme nt in many European countries, but has not yet been approved in the US. A 4-year prospective placebocontrolled trial in 202 women compared calc ium supplementation (1.5 glday) with calcium 1.5g plus sod ium fl uori de 75mg daily. Although the fl uoride treatment group had signi ficant increases in bone mineral density. there was no signifi cant difference in the nu mber of vertebral fractures between the contro l and treatment grou ps, a nd significantly grealer numbers of non vertebral fractures occurred in the fl uoride treatment group. Fluoride appeared to increase the forma tion of trabecular bone at the expense of cortical bone. which may increase the fragility of the skeleton (Riggs et al. 1990 ). However, this US stud y used slightly higher dosages of PharmacoEconomics 5 (6} /994 fl uoride than were used in European studies that have shown a benefi cial effect on fracture rate. Sodiu m fl uoride in lower dosages (50 t o 65 mg/day) with calcium supplementation (1.5 glday) given for 28 ± 18 months reduced spinal fractu re rates significantly in a re trospective study (Farley et al. 1 992) .
Although many o f these agents are considered e ffective in the p reventio n of osteoporosis, HRT is t he only therapy that also offers alleviation of menopausal symptoms and urogenital estrogen defic iency (see Whittington & Faulds 1994) , and the additional benefit of reduced cardiovascular risk. Therefore, for postmenopausal women estrogenbased HRT appears to be the p r eferred therapeutic option, either alone or in combinatio n with calcium supplementat ion.
Overview of Pharmacology of Hormon e Replilcement Therapy (HRT)
The various estrogens and progestogens used in HRT form ulations. their effects on sex hormones and the re productive organs. their pharmacokinetic properties and their efficacy in t he treatment of menopausal symptoms a nd urogenital estrogen deficiency have been comprehe nsively r eviewed (Whittington & Faulds 1994) . There are also many comprehensive rev iews available t hat discuss the pharmacology of HRT formulations (A nsbacher 1993; Balfour & McTavish 1992; Christiansen 199 1; Corson 1993; Elleri ngton et al. 1992; Selby et al. 1989; Steingold et al. 199 1; Winkler 1992; Wiseman & McTavish 1994; Wren 1992) , and only a brief summary of the main fin dings related to effects on osteoporosis and cardiovascular parameters is presemed here.
Effects on Parameters of Bone Metabolism
Measurements of bone mineral density using d ual photon absorptiornetry, dual energy x-ray absorptiornetry, and single photo n absorptiometry have indicated preventio n of bone loss and i ncreased bone mineral content in the spine, forearm and calcaneus with HRT (table IV), which are maintained over longer term (~2-year) study periods (Christiansen & Riis 1990 ; Marslew et at. 1992; ; Ribot et al. 1 992) . Patients in these studies were postmenopausal women who received either oral conjugated equ ine estrogens or oral estradioL in combination with progestogens. Bone-conserving effects of es trogen s were not impaired. and may in fact be enhanced, by concomitant progestogen therapy. Continuous therapy may be more beneficial than cyclic therapy wi th estrogens plus progestogens (Pors Nielsen et al. 1994) . Long term percutaneous estradiol plus testosterone was al so effective in maintaining bone density after menopause (Gamen et al. 199 1; Holland et al. 1994; ). Tibolone, a steroid with weak progestogenic, estrogenic and androgenic propenies, exhibited a similar efficacy in preventing bone loss in postmenopausal women (Lindsay et al. 1980) , and increased bone mineral density in women with established osteoporosis (Geusens et al. 1991) .
Serum calcium levels significantly decreased when patients received calcium supplements in 525 conjunction with estrogen plus progestogen therapy, compared with untreated patients (Adami et al. 1992) , or with pat ients who received either placebo or calcium alone (Aloia et al. 199 1) . Aloia et al. (1991) also observed an increase in serum calcitonin levels. in contrast to studies with HRT that did not include calcium therapy (Resch et al. 1990 ). Transdermal estradiol (O .OS mg) and oral formulations of conjugated estrogens (0.625 mg/day), both given with sequential progestogen therapy, produced comparable reductions in seru m calcium, phosphate and alkaline phosphatase levels during 18 months' treatment (Stevenson et a1. 1990) . Total body calcium increased significantly in postmenopausal women receiv ing HRT plus calc ium supplementation over an average period of 2.9 years, compared with placebo and with calci um supplementation alone in a placebo-controlled trial (Aloia et al. 1 994) . Urinary excretion of calcium and hydroxyproline. which provide furt her indirect evi- Di rect measurements of osteoblastic activity ha ve been difficuh to establish. but the presence of the carboxy terminal propeptide of Type I collagen (Plep) in serum is indirect ev idence of Type I collagen f or mation, which is the major function of osteoblasts. Hassageret al. (1993) observed a 20% increase in PCl P levels in postmenopausal compared w ith premenopausal women, w hich was reduced to pre menopausal levels in women who received HRT. Increased Type III collagen levels in the sk in and increased skin t hickness have also been demonstrated with HRT, e ff ects that appear to reflect collagen cha nges in bone (Maheux et aL 1994; Savvas e t al. 1993) . Transdermal estradiol significantly increased insulin-like growth faclOr-J (lOF-I , mecasermin) in postmenopausal women. which may also be correlated to anabolic processes in bone (S low inska-Srzednicka et a l. 1992).
Osteoporos is is a well recognised complication of rheumalOid arthritis. possibly due in part to the decreased mobility of these patients. In postmenopausal women with rheumatoid arthritis. HRT increased bone mineral d ensity in the l umbar spine (Sambrook et al. 1992; van den Brink et al. 1993a) and in the femoral neck (van den Brink et al. 1993a ). compared with placebo. Evidence suggested that HRT had no direct effect on the di sease activity of rheumatoid arthritis. as di sease parameters r emained unchanged (van den Brink et al. 1993b ). In contrast. significant improvements in d i sease acti vity were noted in pati ents who had se rum estradiol levels> 100 pmollL after 3 and 6 months of transdermal estradiol therapy (Hall & Spector 1993) . In postmenopausal women who were concurrently receiving prednisone, estrogen and progestogen therapy stabi lised spinal bone minerai loss, to a similar extent as in women who r ece ived estrogen and progestogen only ( Clements et al. 1993; Lukert et al. 1992 ). Postmenopausal women who were t aking th yroid hormone concomitantl y with PhannacoEconomics 5 (6) 1994 estrogen had significantl y higher bone mineral densi ty levels t han women who were taking th yroid hormone a lo ne (Schneider et al . 1 994) . HRT may inhibit parathyroid hormone whi ch stimu lates bo ne resorpt ion. Biochemica l indices o f bo ne resorpti on inc reased signifi cantl y less following parathyroid hormone infusion in me nopausal women receiving HRT compared with similar untreated women . In add ition , e str ogen-treated postmenopau sa l women showed greater suppression of parathyroid honnone fo llowing exogenou s calcium infusion (Zofkova et al. 1993) . However, effects on calcitoni n do not appear to be involved as levels are r educed in HRT recipients (Fletcher et al. 1991) . Recent stud ies ind icate that HRT inhibits the activity of inte rleukin-\ , a potent stimul ant of bone resorption wh ich i s usually more a ctive after menopause (Paci fi ci et al. 1993).
Cardiovascular and Serum Lipid Effects
Epidemiological data show that estrogens provide protection against cardiovascular disease in postmenopausal women; Ihis protective effect may be partly mediated b y c ha nges in the plasma lipid and lipoprotei n p r ofi les. Oral unopposed estrogens and, to a lesser extent, percutaneous estradiol induced decreases in to tal cholesterol and LDLcholestero l, and increases in HDL-cholestero l (table V). Serum lipid changes were observed within the fi rst week of therapy, were maintained with continued therapy, and were proportional to the dosages given . The rise in HDL-cholcsterol was partiall y negated by concomitant progestogens (Kim et al. 1 994; Marsh et al. 1994) , altho ugh 1 0 to 20 mglday of dydrogesterone for 14 days per cycle d id not appear to have this effect (van der Mooren et al. 1992) . Furthermore, an epidemiological study in 4958 postmenopausal women found no difference in HDL-c holesterol levels with estrogen or estrogen plus pr ogestoge ns (Nabulsi et al. 1993) . In t his s t ud y. the majority of women using HRT received conjugated equine estrogens with o r without medroxyprogesterone acetate. (1991 ) Haenggi et al. (1993) ; Hickol<. at ai, (1993) ; Marsh et al. (1994) SoIaji et al. (1993) ; Cortellaro et al. (1991) ; Lobo ( Bar et a!. (1993) Nabulsi et ai, (1993) ; Steingold at al. (1991 ) Enzelsberger et al. (1991) Haarbo et al. (1991) a Un less otherw ise stated, pharmacodynamic ellects are assumed to be similar for all HAT formulations.
Abbreviations and symbols: AT-III = antithrombin III: ATP = adenosine triphosphate: CPA = cyproterone: E = estrogen: E2 = estradiol; HOL = high density lipoprotein; L = levonorgestrel: LDL = low density lipoprotein; N = norgestrel; OCE = oral conjugated equine estrogens; DE2" oral estradiol; p" progestogen; PE2 = percutaneous estradiol; TDE2 = transdermal estradiol; lib" tibolone; VLDL = very iow density lipoprotein; t = Increase in; ! = decrease in: H no change in; " " has a greater eflect than .
Not all studies have reported similar changes; a 2-month trial noted a si gnificant decrease in triglyceride levels w i th percutaneous estradiol compared with oral micronised dosages, but no changes in other lipid parameters (de Moustier et al. 1989) . Other comparati ve studies of transdermal estradiol 0.05 mg/day and conjugated estrogens 0.625 mg/day, both administered in conjunction with medroxyprogesterone acetate 10 mg/day for 8 days per cy-:;le, observed significant reductions in tOlal and LDL-cholesterol in both groups, but a significant decrease in triglyceride levels was seen only in women receiving transdermal estradiol (Cortellaro et al. 1991) . Decreased levels of HDL-cholesterol were noted in postmenopausal women who received oral tibolone 2.5mg for 6 months (Haenggi et al. 1993) , It seems likely. therefore, that the dosage regimen may have a considerable role in determining the effect of HRT on the lipoprotein profile (Jensen 1992 ( Hickok ct al. 1993; Marsh ct al. 1994 ). In conlrasl, eslrad iolllO 2 mg/day plus norethisterone acetate 1 mg for 9 days per cycle did not alter lipid paramete rs during a 2-year prospective study . A 2-year stud y of transdermal estradiol with or without medroxyprogestero ne acetate showed decreases in total and LDL-cholesterol, while other lipid parameters remained unchanged (Pang et al. 1993) .
Oxidative modification of LDL is thoughlto be atherogenic. and Ihe anl ioxidant effect of estrogen may therefore influence the development of coronary artcry atherosclerosis. Siudies in the cyno molgus monkey model have indicated reduced LDL uptake in coronary arteries afte r estrogen administration (reviewed in Clarkson et al. 1994) . Onset of LDL oxidation was s ignificantly delayed in women receiving intra-arteria l o r transdermal estradiol. and returned to baseline values aflcr discontinuation of therapy (Sack e t al. 1994) .
Reducti ons in lipo protein(a) level s have been observed wi th ora l estrogen and progeslOgen therapy in postmenopausal women (Soma et al. 1993; van der Mooren et aJ. 1992; Wolfe & Huff 1993) , and with tibolone therapy (Haenggi et al. 1993) , wh.ich suggests that this may be a mechanism for the beneficial effect of HRT. However, unopposed estradiol in low dosages did not produce significant changes in li popro le in(a) leve ls (Fari s h el al. 1993) . In postmenopausa l women with noninsulin-dependent diabetes, HRT with subcutaneous esuadiol plus oral progestogen maintained plasma esuadiol levels hut did not alter plasma lipid levels PharmacQ£cononrics 5 (6) 1994 compared with similar untreated women (MosnierPudar et al. 1991 ) .
Estrogen and progestogen therapy has been observed to prevenlthe central distribution of body fat, which has been recognised as an independent predictor of cardiovascular d isease (Haarbo et al. 1991 ) .
These effects do not fully account for the cardioprotective effect of estrogens, and other mechanisms have been sought. Reis et al. (1994) o bserved in postmenopausal women with stable angina, atypical chest pain or who had an abnormal electrocardiogram with exercise. that estrogen significantly increased coronary blood flow, decreased resistance, and increased epicardial cross-sectional area compared wi th placebo. Furthermore, abnormal coronary vasomOlOr responses 10 acetylcholine were attenuated with estrogen administration.
Transient increases in peripheral vasodilatation and decreases in systemic vascular resistance. which were no longer apparent after I year of therapy, have been nOled in women receiving HRT. Thcre was a positive inotropic effect which was maintained after I year of therapy (Pines et al. 1992) . In this study. women received oral conjugated estrogens or transdermal estradiol. plus oral medroxyprogesterone acetate for 9 or 12 days per cycle. ProgeslOgen and estrogen therapy induced sign ificant decreases in syslOlic, diastolic and mean arterial blood pressure (Regensteiner et al. 1991) . In addition, the reduction in ri sk of coronary heart di sease may be partially mediated by HRT-induced changes in haemostatic mcchanisms (reviewed in Winkler 1992; tablc V).
Benefits and Risks Associnted with HRT
The risks and benefits of HRT are important considerations from many perspectives. For socie ty as a whole the risks and benefits of HRT playa major role in detennining the fina l cost-effectiveness of thi s therapy, and, in some cou ntries, which patient groups are considered eligible fo r therapy. For the individual patient receiving HRT, benefi ts o f long term prophylaxis against osteoporotic frac ture and cardiovascular disease need to be weighed against the inconvenience of prolonged menstruation and the risks o f endometrial cancer, gall bladder disease and possible breast cancer. Further considerations are the influence that prior hysterectomy, surgical vs normal menopause, and opposed vs unopposed estrogen replacement therapy may have on the magnitude of associated risks and benefits.
The risks and benefits of HRT in the treatment of menopausal symptoms and/or the consequences of urogenital estrogen deficiency are discussed by Whittington and Faulds (1994) , as are the l ocal and syste mic tolerability profiles of the various available preparations. The following sections discuss the long term risk-benefit profile of HRT. An example of relative ri sk rates for women receivi ng 10 years of HRT is outlined in table VI. These particular risk rates were used in a major pharmacoeconomic analysis (Daly e t a l. 1992): other analyses may differ depending upon the epidemiological evidence available and t he assumptions and parameters used in each study.
Osteoporotic Fracture
The lifeti me probability of hip fracture for a 50-year-old White woman in the US is 15 %, with a 1.5% probability of death due to hip fracture. Women aged ~ 75 years are particularly at risk (section 1.1. 1). Ri sk rates that have been reported in meta-analyses of epide miological trials differ from those used in 529 pharmacoeconomic analyses; and these in turn are not entirely supported by current clinical evidence. Therefore. an examination of the clinical efficacy of HRT in osteoporosis is warranted, in order to assess the validity of risk assumptions and the consequent accuracy of cost analyses.
Effects on Bone Density
Several trials in postmenopausal women have indicated that prevention of bone loss and, in some cases, a modest increase in bone mineral density, is achievable with oral conjugated estrogens 0.625 mg/day or with transdermal estradiol 0.05 mg/day, either with or without progestogens Felson et al. 1993; Field et al. 1993; Luciano et al. 1993; Stevenson et al. 1990 ). There may be a dose-response relationship between transdermal estradiol and prevention of bone mineral loss (Field et al. 1993) . However, clinical experience with transdennal estradiol in the prevention of osteoporos is is relatively limited with the majority of in vestigators monitoring bone mineral density at a single site. Results from a 48-weck placebocontrolled study in peri-or postmenopausal women with rheumatoid arthri tis indicated that spinal bone density improved with transdermal estradiol, but that bone density at the hip remained unchanged (MacDonald et al. 1993) . Abbreviations: E "unopposed estrogen replacement lherapy; E + P" estrogen plus progestogen.
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Cessalion of HRT is followed by a period of rapid bone loss, similar to that observed in untreated women at the onset of menopause. The protective effect aflong term HRT is therefore greatest at the end of trcalmen! and will have decreased to approximately half after a IO-year period following treatment for 10 years (Ettinger & . Thu s, even 10 years of HRT cannot be expected to confer protection over the entire remaining lifespan. A study in 670 women of mean age 76 years indicated that only women aged < 75 years who had taken eSlrogen for ~ 7 years had a bone minerai density notably greater(;?: 10%) than untreated women. In these women, duration of therapy correlated with bone mineral density. For women aged;:: 75 years in the same study, the effect of prolonged estrogen therapy was much less pronounced and did not correlate with treatment duration. Compared with untreated women, mean bone densi ty was 3.8, 8.0 and 2.7% higher in women treated for 5 to 6, 7 to 9, and;:: 10 years, respectively (Felson et al. 1993) . Most of these women had ceased therapy;:: 12 years before bone mineral density was measured, which suggests that the duration of therapy may have been too short to sustain an effect after age 75 years. An alternative explanation is that protection conferred by estrogen therapy may reduce with increasing age (Ettinger & Grady 1993) . A concern with case control studies is that women used as controls may have higher bone density at baseline. and therefore are not representative of women with low bone density among whom excess mortality is 20% even in the absence of fractures (Kanis & Stevenson 1994) . Further analysis of the dala from the trial by Felson et al. ( 1993) was performed to address these concerns, but little difference was found in the final outcome (Felson & Zhang 1994) .
Comparative Effects
Comparative clinical trials have evaluated a variety of estrogen preparations, and other boneconserving agents as prophylaxis. A long tenn (mean 3.7 years) study of unopposed estradiol valerate 1 mg/day or conjugated estrogens 0.625 mg/day indicated that bone mineral loss was not signifi -
cantly different between groups, but that bone minerai density reduced slightly over the study period (Duursma et al. 1992) . A comparison of transdermal estradiol 0.05mg plus norethisterone acetate 0.25mg and oral conjugated estrogens 0.625mg plus norgestrel found that both treatment regimens increased bone mineral density, although the rate of change in bone mineral density varied considerably between different anatomical sites (Stevenson et al. 1990) . Differences between study r esults may also be attributable to the additive effect of progestogens: progestogens given as monotherapy have been shown 10 partly counteract early postmenopausal bone loss (TremoIW~res et al. 1993) . A 2-year comparative study of conj ugated estrogens plus progestogen, calcitonin, and a combination of these agents in early postmenopausal women showed that whereas both HRT and calcitonin regimens were effective in preventing bone loss. the combination of calcitonin plus HRT increased vertebral bone mass by 9.2% after 2 years of treatment (Meschia et al. 1993) .
Bone loss continued with calcium supplementation, but improved with HRT in the early postmenopausal period in comparative trials (Fioretti et al. 1991; Ringe & Meiss 1993) . In a long term (mean 2.9 years) study of 118 postmenopausal women receiving calcium supplementation with or without HRT or placebo, bone loss was significant ly reduced in both treatmen( groups. Women who recei ved calcium supplementation plu s HRT had the greatest reduction in bone mineral loss (Aloia et al. 1994) .
More extensive compari sons have been performed to determine the effects of 6 different regimens on bone mineral density. Groups of 20 patients received either: i) transdennal estradiol 0.05 mg/day plus progestogen 10 mg/day for 10 days per month; ii) intranasal synthetic calcitonin 100 IV/day; iii) clodronic acid (clodronate) 400 mg/day; iv) nandrolone 50mg every 3 weeks; v) calcium 600mg plus sodium fluoride 20mg (daily frequency unknown); vi) ipriflavone 200 mg/day. Preliminary resu lts indicated that bone mineral density increased by 1 to 6% in all groups after 6 months, from a mean level of 0.85 ± 0.12 g/cm 2 (Di Renzo et a1. 1993). Another small study comparing etidronic acid plus calci um suppleme ntation with percutaneous estradiol indicated that bone mineraI loss was prevented equally in both groups of postmenopausal women (Chaouat et a1. 1993) .
Effects 011 Fracture Incidence
Although increased bone density is correlated with a r eduction in fracture incidence. only a limited number of trials have determined the effect of HRT on fracture rate. Preliminary results of a l ong term retrospective study found that HRT reduced and delayed the incidence of wrist and vertebral fractures. but did not alter the incidence of hip fractures. In this study, the mean duration of HRT was 17 years (minimum 5 years) and the mean followup after treatment was 7.3 years (Maxim & Ettinger 1993) . Kanis (1993) suggested that a high fa lsepositive rate affects the apparent inc idence and prevalence of vertebral fracture. and thus may influence the outcome of clinical trials evaluating this parameter. Another retrospective cohort study indicated that HRT reduced the relative risk of all osteoporotic fractures 10 0.5. and the re lative risk of fracture to the distal radius to 0.18 after 5 years of therapy: nonosteoporotic fracture risk was unchanged. These investigators al so noted a lower than expected incidence of hip fracture in women who received HRT (Spector et al. 1992 ). In contrast, preliminary results of a meta-analysis of 47 randomi sed controlled trials,S cohort and 9 casecontrol studies indicated that pooled relat ive risk ratc was 0.5 for case-control and 0.84 for cohort studies. Ini tial outcomes did not support mass intervention with HRT as an effective mean s of osteoporotic fracture prevention, as estimates of absol ute r isk reduction indicated that 300 to 2000 person-years of treatment were necessary to prevent I hip fracture (Robertson et al. 1993) . Final results of this analysis will indicate whether sufficient considerati on has been given to the likeli hood of excess mortality influenci ng outcomes.
Reports from an earlier but more comprehensive meta-analys is i ndicated a reduction in the risk of hip frac ture with HRT. with a poo led estimate 531 of relative risk from II epidemiological studies of 0.75. Data suggested the relative risk would further decrease to 0.5 after ~ 10 years of therapy. Although dose-response data were limited, 0.625mg estrogen daily appeared to convey a protective effect . Combined estroge n and progestogen were assumed to r esult in similar risk reductions to unopposed therapy (Grady et al. 1992 ).
Effects in Established Osteoporosis
Few trials have examined the efficacy of HRT in established osteoporos is. Lufkin et al. (1992) observed that transdermal estradiol improved bone mineral den si ty and decreased the incidence ofvertebral fracture in postmenopausal women with previous clinical evidence of;:: I osteoporotic fracture in a I-year, randomised, placebo-controlled trial. Funher confirmation of these results is awaited with interest.
Risk Rates Used in Pharmacoecollomic Analyses
Pharmacocconomic studies that have assessed the cost effectiveness of fracture prevention, have usually based thei r data on a retrospecti ve. casecontrol. I-year study performed by W eiss et al. ( 1980) . who determ ined a relative risk of 0.43 for current users of estrogen (Cheung & Wren 1992; Dal y et al. 1992; Weinstein & Schiff 1983) . In general, a relative risk of 0.5 has been used ).
Effects of treatment dumtion have also been considered. A number of pharmacoeconomic analyses have assumed a relmive risk of hip fracture of 0.8 for the first 5 years of treatment and 0.4 thereafter, with the risk increasing gradually after cessation of treatment (Cheung & Wren 1992 : Daly et al. 1992 Roche & Vessey 1990; Weinstein & Schiff 1983; ). Other studies have used more complex means to determine changes in relati ve risk with age and duration of therapy. Clark and Schulli nga ( 1992) assumed a r eduction in risk of 50% for all fractures after 5 years of HRT and assumed thaI therapy continued for 15 years. Risk rates for hip fracture, venebral fracture, and other fractures were estimated in high-, mid-and low-risk categories determined by bone mineral density sc reeni ng, and cost analyses were based on the estimated an nu al incidence of fracture for each group. Weinstei n ( 1 980) assu med a r elative risk of 0.33 while patients received HRT, and 0.5 for a period after ceasing therapy equi valent 10 that of ils duration. Tosteson el al. (1990) assumed that HRT would prevent bone l oss for the durati on of therapy a nd used their computer Siffi ulalion model 10 show that t his assumption was consistent w i th the relative risks reported in epidemiological studies. Women aged 50 to 74 years had an eSli mmed re lative risk of 0.84 and 0.52 after 5 a nd 10 years of HRT, respectively.
Cardiovascular Disease
Ischaemic heart disease is a leading cause of death amo ng postmenopausal women in Western societies. The median age of death fro m i schaemic heart disease is 74 years in White women, and at age 50 years the lifetime probability of dy ing fro m heart disease is 31 %. Women with early men opause are particularly at risk (Grady et al. 1992) .
Efficacy
The effects of HRT on cardiovascular disease appear to be caused by a variety of mechanisms, includ ing effecls on serum li pid profi les, an ant io",idant effect that delays atherogenesis, increased coronary blood flow, reduced peri pheral resistance and ant icoagu lant effects (section 3.2). Oral conj ugated estrogen has been approved as a primary indication i n t he prevention of coronary heart disease in Me"'ico. Pakistan, Argenti na, Australia and Chil e, and many countries have approved cardioprotection as an additional benefit o f estrogen therapy. Much of the evidence supporti ng this clai m has originated from epidem io logical stud ies rather than clinical trials. To date, there have been no randomised Irials to determ ine the effect of estrogen on the subsequent developme nt of symptomatic coronary heart disease ( Conti 1993) .
Several st udies have considered the e ffect of estrogen use on coronary artery occlusion in postmenopausal w o men. In a study of 933 postmeno-
pausal women who u n dcIWcnt coronary angiography, Gruchow et al. (1988) reported that users of estrogen had significantly lower degrees of occl usion than non-users. Other stud ies have confirmed this fin ding (McFarland et al. 1989; Sullivan et al. 1988 ). Nonusers al so showed a signifi cant increase in occl usion scores wi th age, an effect not ev ident in current users of estrogen (Gruchow et al. 1988) . Sulli van and associates (1990) exami ned the effect of estrogen use on cardiovascular disease and survival over 10 years, and fo und that estrogen therapy prolonged survival if coronary occl usion was present, but had l ess effect in the absence of coronary artery disease. 10-Year survival was 60% of women wi th 70% coronary stenosis who had never used estrogen, compared with 97% of women who had ever used estrogen. 85% of women wi th mild or moderate coronary stenosis who had never used estrogen were alive after 10 years, compared with a IO-year survival of 95.6% for wo men who had ever used estrogen (S ull ivan et al. 1990) .
A wide variety of endpoi nts have been used in epidemio logical studies that have e",ami ned the effects of HRT on cardiovascul ar disease. These incl ude fatal coronary heart d isease, fatal and nonfa tal myocardial infarc tion, coronary stenosis, and sudden death. The majority of studies show a statistically significant reduction in the ris k of subsequent ischaem ic heart disease with postmenopausa l estrogen therapy, with r esults from meta-analyses esti mating a relative risk of 0.55 to 0.65 in women who have ever used estrogen compared with women who have never used estrogen (reviewed in Grady et al . 1992; Harlap 1992; Wren 1992) . Preli minary studies indicate t hat prolonged duration of therapy may reduce the relative risk, but further research is needed to confirm these results (Henderson et al. 199 1) . The effec t of dose on the level of ris k reduction cannot yet be determined, although conjugated estrogen 0.625 mg/day appears to be cardioprotective (Grady et al. 1992 ).
Effects of Estrogen Plus Progestogen
Estrogen plus progestogen may attenuate the beneficial effect of estrogen on seru m lipid pr ofiles, but thi s mechan ism is on ly partly respon-sible for the cardioprotective effect and depends on the type of progestogen used (Grady et al. 1992 ; secti on 3.2). Nahulsi et al. ( 1993) used a c ross-sectional analysis and found that women using estrogen (usually oral conjugated estrogens) plus progestogen (primari ly medroxyprogesterone acetate) would have a greater beneficial effect than women receiving unopposed estrogen. This study examined the effects of HRT in postmenopausal women who were free of cardiovascular disease on their baseli ne visit. Women who currently used estrogens had hi gher leve ls of HDL-cholesterol and apolipoprotein AI. but lower levels ofLD L-cholesterol, apolipoprotein B, lipoprotein(a), fibrinogen and antithrombin III than nonusers. In addition to these benefits. women who used estrogen and progeslOgen also had lower serum triglyceride. factor VII. and protein C levels than women who used unopposed estrogens. These findings were estimated to result in a 42% reduction in the relative risk of coronary heart disease in users compared with nonu sers of HRT. Although thi s study did not use clinical endpoin ts. the physiolog ical changes observed suggest that relative risk rates may decrease a further 18% wit.h combined therapy. Randomised trials are required to eliminate the possibi lity that these effects are due to se lection biases. Roche and Vessey (1990) . and Daly et al. ( 1992) took therapy duration into account in their pharmacoeconomic analyses and assumed that heart disease risk reduced by 25% after 5 years and 50% after 10 years of unopposed HRT. with the risk remaining reduced after cessation of treatment for a period equal to that of the treatment. Other analyses have generally assumed a 50% reduction in risk with unopposed therapy (Cummings et 
Risk Rates Used in Pharmacoeconomic Analyses

Cerebrovascular Disease
A 50-year-old White woman has a 20% lifetime probability of developing stroke and an 8% probability of dying from stroke. The median age of women dying from stroke is 83 years. Study finding s reported from 1970 to 1992 are not consistent, but using these results Grady et a!. (1992) estimated a relat ive risk of 0.96 for stroke among estrogen users. However. two recent large cohort studies estimated the re lative risk of any stroke to be 0.69 (Finucane et al. 1993) and 0.90 (Falkebom et al. 1993) for estrogen users, and the relative risk of stroke mortality as 0.37 (Finucane et al. 1993) . Women who had been prescribed estradiol and levonorgestrel had a r educed risk of stroke (0.6 1), as did women aged < 60 years at trial entry (risk of any stroke = 0.72) [Falkebom et a l. 1993) .
Risk Rates Used in Pharmacoecollomic Analyses
In phannacoeconomic analyses. Oal y et al. ( 1992) assumed that relative risk of stroke with unopposed estrogen therapy was 0.75 to 1.0. dependi ng on duration of therapy. Relative risk with combined estrogen and progestogen therapy also varied with duralion of therapy. but the maximum benefit of therapy was presumed to be reduced, wi th a relati ve risk of 0.88 to 1.0 (table VI). I n contrast. Roche and Vessey ( 1990) assumed that the effect of HRT on stroke was the same as that for ischaemic heart disease: a 50% or 25% reduction in risk after 10 years of unopposed estrogen or combined therapy, respectively. The benefits of both forms of therapy were assumed to be halved at 5 years' duration of treatment, and to continue after HRT cessation for a period equal to the duration of Ireatment.
Endometrial Cancer
A White woman aged 50 years has a 2.6% lifetime probabili ty of developing endometrial cancer (Grady et al. 1992) . Five-year relative survival is 93% for stage I d i sease, and 84% for all stages combined (HarJap 1992). Vaginal bleeding is an earl y symptom, which usualJy leads to prompt diagnosis and a favo urable prognosis . However. the increased vaginal bleeding associated with estrogen therapy may imroduce detect ion bias, as women with previously undetected asymptomatic e ndometrial cancer are likely to seek medical advice if estrogen ini tiates uterine bleedi ng. T his may partiall y explain why the morta lity rate of endometrial cancer has remained unchanged, despite variations in incidence (Grady el al. 1992 : HarJap 1992 .
However, Herri nton and Weiss ( 1993) suggest that detection bias is unlikely to have a major effect on the risk of endometrial cancer when estrogen is used for;?: I year.
Between 1970 to 1991, approximately 35 casecontrol and cohort studies examined the association betwee n HRT and endometrial cancer (reviewed in Grady et al. 1992) . The majority of studies in postmenopausal women receiving u nopposed estrogen have indicated a positive relat ionship between duration of therapy and r isk an d, to a lesser extent, dosage and risk. The pooled estimate of the relative risk of endometrial cancer in women who have ever used (compared with women who have never used) estrogen was 2.3 1. For women who have used estrogen for;?: 8 years. the relative ri sk was 8.22, but some data incl uded in this pooled estimate were from women receiving high dosages of estrogen. Two studies in women who received conj ugated estrogen 0 .625 mg daily for ;;:. 5 years indicated risk ratios of 4.3 and 4.8 (Grady et al. 1992) . There appear to be no differences in r i sk with cyclic compared with conti nuous r egimens of uno pposed estrogen, but differences due to the type or formulation of unopposed estrogen remai n unresolved (Herri nton & Weiss 1993) .
Most reviewers of epidemiological studies of HRT agree that the relative risk of developing e ndometrial cancer in women receivi ng estrogen opposed by progestogen is the same as that in untreated wo me n (Grady et al. 1992; Harlap 1992) . In a recent retrospective study in women taking Pharrn(ICoEconomics 5 (6) 1994 HRT for a mean of 4.4 (range 0 .3 to 7.2) years, abnormal vaginal bleeding occurred in 23.2% of HRT recipients compared with 7.5% of age-matched untreated women. Relative risk of endometrial biopsy and curettage was 3.4 and 1. 5, respectively, in treated compared with untreated women. However, endometrial cancer d id not develop in either group o f pat ients (Ellinger et al. 1993) . The majority of treated women in this tri al received o ra l conj ugated estrogens 0.625 mg/day and medroxyprogesterone acetate 10 mg/day for JO days per cycle.
Progestogens have been used to prevent endometrial hyperplasia which may be a p recursor to endometrial cancer, but there is some evidence to suggest they also reduce the benefit of unopposed estrogen i n p revention of cardiovascular di sease (section 3.2). For this reason, until more defini ti ve dala suggest otherwise, the additio n of progestogen to HRT is usually recommended only in women with intact uteri (Goddard 1992) .
1 Risk Rates Used in Pharmacoeconomic Analyses
Pharmacoeconomic analyses have used re lative risks for endometrial cancer that were adj usted fo r the age of the patient and the duration of therapy. Relative risk was estimated as 4.0 after 5 years of unopposed estrogen therapy (0.625mg dai ly), 8.0 after 10 and 15 years of therapy, reducing to I .0 ten years after therapy was discontinued (Cheung & Wre n 1992; Weinstein & Schiff 1983; ). Case fatality rate was assumed to be \0% and the cost of treatment (including hysterectomy and subsequ ent radiotherapy) was estimated as SUS3200 per case in the US in 1980 (Weinstein 1980 ) and as $US4900 in 1988 (Wei nstein & Tosteson 1990) . Simi lar cost estimates performed in Australia resulted in an overall cost of $A4370 per case (1988 Australian dollars) rCheung & Wre n 19921. Rov ira and Tri nxet ( 1993) based their calculation of the cost of endometrial cancer on data concerning ovarian cancer and reported costs of Pta800 000 per case in Spain (1989 pesetas).
In contrast, Daly et a1.
( 1 992) assumed a maximum risk of 6.0 follow ing 5 years of unopposed estrogen therapy, returning to normal 5 years after withdrawal of treatment. In this UK study the cost per admiss ion for endometrial cancer was estimated to be £ 1 040 to£2190 depending on the age at admission (personal communication Dr. E. Daly). Hospital admission costs were based on age-and disease-specific average inpatient duration of stay. and therefore did not include costs of subsequent radiotherapy.
Other investigators have assumed no additional risk for women receiving estrogen and progestogen therapy and therefore have omitted thi s factor from their cost analyses (Clark & (Cheung & Wren 1992 ) outcomes were more favourable in women with hysterectomy (sec section 6).
Breast Cancer
Women have a 1 in 12 lifetime risk of developing breast cancer. with the risk increasi ng with age and late onset of menopause (Hil lard et al. 1991) . The median age at which breast cancer develops is 69 years (Grady et at. 1992) , and the mortality rate and incidence differ between countries (Mann 1992) . The numerous (> 50) studies (including 5 metaanalyses) intended to clarify the risk of breast cancer associated with HRT have been exhausti vely analysed and reviewed. and this section i s based on these analyses.
Evidence for an increased risk of breast cancer with HRT is conflicting. In generaL the findin gs of meta-analyses to date indicate a small increase in risk with long term use of estrogen (25 to 30% increase in risk for women receiving estrogen for > 8 years) and no increase in risk with any or short tenn use of estrogen (Grady et al. 1992 ; Grady & Rubin 1993; Henrich 1992) . The innuence of detection bias on study conclusions remains uncertain (Grady el at. 1992; Harlap 1992) . and few studies were controlled with respect to alcohol intake. which has also been positively linked with an increased risk of breast cancer (Zumoff 1993) .
A meta-analysis (Dupont & Page 1991 ) indicated that therapy consisting of conjugated estrogen dosages :s 0.625 mg/day did not increase the risk of breast cancer. Investigations of the innuence of progestogen-containing regimens on the risk of breast cancer have yielded conflicting resull~ (DiSaia 1993; Khoo 1993; Speroff 1992) . Nevertheless. there is some ev idence to indicate that long term use of HRT with progestogens may actually reduce the risk of breast cancer (Gambrell 1993) . Animal and in vitro studies have ind icated that progestogens oppose the proliferative effects of estrogen on mammary (issue (Musgrove et al. 1991; Sitruk-Ware 1994) . Preliminary studies in patients with previously treated breast cancer who received HRT suggest that there are no obvious adverse effects directl y attributable 10 HRT (Wi le et al. 1993) , and in fact mortality rates may be improved in these patients (Gambrell 1993) . Accordingly, a definitive relative risk estimate is not feasib le at present for breast cancer in patients receiv ing HRT, but a s mall re lative ri sk of approx imately 1.3 is probable with long tenn therapy.
4,5.1 Risk Rates Used in Pharmacoeconomic Allalyses
Pharmacocconomic analyses have used various approaches to deal with this issue, In the UK. Daly et al. ( 1992) assumed that 5 years of HRT did not increase risk. but that relative risk increased to 1.3 and 1.5 after 10 and 15 years of treatment. respecti vely, The risk was assumed 10 remain elevated after treatment cessation for a period equal to thai of treatment. Roche and Vessey (1990) used a similar formula and estimated £ 1200 as the cost for each hospital admission.
Wein stein (1980) did not include breast cancer in base line pharmacoeconomic estimates. but used a relati ve risk rate of 1.5 and costs of $US3500 in subsequent sensiti vity analyses. These costs were calculated in 1980 US dollars and included mastectomy, hospitalisation , breast prosthesis and radiotherapy. Other US studies applied relative ri sk rates of J .25 (Weinstein & Schiff 1983; ) or 1.36 (Tosteson & Weinstein 1991) 10 national age-specific incidence rates in the US. In these stud ies. the commencement of increased risk and its duration after cessation of treatment varied considerably. Costs of treatment included biopsy. mastectomy. rad iotherapy and prosthesis costs, and the average cost per case was estimated to be $US4000 in 1982 (Weinstein & Schiff 1983) ,
Costs of breast cancer assessed in an Australian setting included mastectomy, hi slO!ogy, hospitalisat ion plus breast prosthesi s; however, longer term therapy includ in g radio therapy or chemotherapy was excluded from the analysis, Overall direct costs were estimated to be $A5607 per case in 1988 and relati ve risk rate was 1.25 (Cheung & Wren 1992 ).
Other Ri sks and Benefits
Oral estrogen therapy also inc reases the risk of gallbladder di sease, which is rarely fatal, but is likely to add to the costs associated with HRT. Gallbladder di sease was considered in earl y pharmacoeconomic studies, and assigned a relati ve risk of 2.5 after 5 years of therapy, lasting unti l 5 years following therapy cessation (Weinstein 1980 ; Wei nste in & Sch iff 1983) . Case fatality rates were est imated as 0.28% for patients aged 50 to 69 years and 1.3 1 % for patients aged ~ 70 years. More recent pharmacoeconomic studies have not included this risk in their analyses, although a recent prospective cohort study of 54 845 postmenopausal wom en reported that 1750 women underwent cholecystectomy during 8 ye ars of foll ow-up, with a relative risk of2.1 in women receiving HRT (Grodstein et al. 1994) .
A prevalence study of age-related eye di sease has suggested that estrogens may have a small protective effect in the development of lens opacities. Current use of estrogens in postmenopausal women was associated wi th decreased risk of severe nu- 1994 clear sclerosi s (Klein et al. 1994) . Further studies to substantiate this report are awaited with interest
S. Other Factors Influencing the Pharmacoeconomic Assessment of HRT
COSIS of HRT
Oral conjugated estrogens with or without proge stogen have been most commonly used to estimate acqui sition costs for HRT in pharmacoeconomic studies (Daly et al. 1992; Roche & Vessey 1990; Tosteson et al. 1990 ). Transdermal products are more expensive than oral formulation s, and combination therapy has a higher acq ui sition cost compared with unopposed e strogen therapy (see Whittington & Faulds 1994 Many studies have considered the use of unopposed estrogen treatment in women with intact uteri. a regimen that is now considered unethical in man y countries due to increased risk of endometrial hyperplas ia and cancer. An Australian study which focussed o n osteoporotic fracture and myocardial infarction . assumed that the costs of HRT would include an nual d rug acquis ition costs. 2 extra general practitioner consultations pe r year, plus the cost of an annual outpatient endometrial biopsy for women with intact uteri on estrogen monotherapy. The cost of 10 years of treatment was $A974 for estrogen only and $A1385 for estrogen plus progestogen therapy (1988 dollars). Monitoring costs for unopposed estrogen therapy in women with intact uteri added an extra cost of $A700 for 10 years of therapy (Cheung & Wren 1992) . Assumin g that endometrial biopsy was performed once every 2 years (rather than annually) reduced treatment costs over 10 years in women rece iving unopposed estrogen therapy (Dal y et al. 1992 ; Whittington & Faulds 1 994). Addi tional monitoring procedures such as mammography, electrocardiography and bone mineral den sitometry would fur-ther add to the costs assoc iated with HRT. Monitoring procedures and t hei r acceptabi lity to t he p atie nt are l ikely to have a major impact. not only on the overall cost of HRT but also on patient compliance (section 5.2; Wh ittington & Faulds 1 994).
Compliance With HRT
Long term (realmen! is req uired to achieve the full protective effect of HRT, commencing a t m e n opause and continuing fo r at least 10 years. The attitudes of palie nts and presc ribing cli nicians, and subsequent effects on compli ance with HRT for me nopausal sy mptoms and urogenital estrogen defi ciency have been reviewed (Whittington & Faulds 1994) . In general, compliance with HRT tends to be low even in symptomatic women, in m ain due to the rel uctance of postmenopausal women t o re-experience cyclic bleedi ng. Studies have indicated that between 5 and 50% of women wi thdraw from therapy, most with in the fi rst year of therapy (Whillington & Faulds 1994) .
A single-centre UK st udy reported that only 6% of p at ients received HRT p r imarily as prophylax is against osteoporos is (Roberts 1991) , which suggests that the majori ty of women were not intending their use of HRT to extend beyond t he symptomatic period. A fu rther UK study (Wallace et al. 1990 ) reported that only 36% of patients offered HRT after distal frac ture of the r adi us agreed to therapy, and you nger patients (aged 50 to 55 years) were more will ing to accept therapy. An Australian study confirmed that on ly 73% of women continued to take HRT 1 year after commencement of therapy ( Wren & Brown 199 1) . Surprisingly, 44% of 206 women w ith a previous history of breast cancer were willing to consider receivi ng HRT under medical supervision, despite a fear that it might precipi tate cancer recurrence. This US study ind icated that although women were concerned about cancer recurre nce, they were al most equally concerned about the risk of osteoporosis and heart disease (VassilopoulouSelli n & Zoli nski 1992). These results may refl ect a high level of awareness about the benefits and risks associaled with HRT among these women.
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For example, al most all knew of the benefi ts in terms of heart disease. whereas in the Norwegian survey reported by Hunskaar and Backe ( 1992) 60% of women were ignorant of the connection between HRT a nd cardiovascular health.
There is litt le agreemen t concernin g the level of compliance with HRT to be expected from the ge neral popul ation of postmenopausal wome n. Two phannacoeconomic a nal yses (Daly et a!. 1992; Rovira & Trin xet 1993) examined scenarios where compl iance reduced over time. with the latter suggesting that as compli ance decreased, so did the cost (Whittington & Faulds 1994).
Clark and Schullinga ( 1992) used a m odel which assumed that a cohort of 100 000 women was categorised by bone mineral densi ty screening. and th at 90.70 and 0% of women at high. moderate or low risk of osteoporotic fracture. respectively. received HRT for 15 years. Results were particularly sensitive 10 compliance in the high-risk group. wi th each 10% increase in compliance by these women increasi ng net savings by $US I.9 million ( 1 988 US dollars). A 10% increase in compl iance in women at moderate risk increased net savings by SUSO.4 million. A U K s tudy assumed a screeni ng uptake rate of 70%. a screening se nsitivity o f 37%. and compli· ance of 30% with 10 years of HRT. This model assumed Ihal risk of fracture reduced by 50% with the effect lasti ng the remainder of the l ifespan . With these ass um ptions. the model predi cted that onl y 4% of fractures would be prevented per year, and that screen ing and HRT costs would nOt be offse t by the reduction in fracture incidence (revie wed in Anon. 1992).
Using a different approach, Ti effenbcrg ( 1993a.b) determined the probabi lity of abandoning treatment based on the Kupperman index and the satisfaction with treatment expressed by wome n within the study. The probability of abandoning treatment was based on the proportion of women who did not show improvement (gain) with the treatment. These investigators estimated that. based on the probability of abandoning treatment. 75.7% of the target popu lation would be effect ively treated wi th transdcrmal HRT compared with 40.3% if the popul mion was Irealed with other HRT formulations.
Cost per year-or-life saved (YLS) was $US31 625 compared with $US44 708. respectively ( 199 1 US doUars), However, because this method was based upon the improvemem in menopausal symptoms, yet was applied to tr eatment of 25 years duration. the validi ty of the outcome may be questionable.
Quality-of-Life Considerations
Changes in quality of life are possible with each of the risk s and b enefits outli ned in section 4, and w ith amel ioration of menopausal symplOms (see Whittington & Faulds 1 994). The quality-of-li fe alterations associated with osteoporosis have nOi yet been resolved. There is a general lack of correlation between the duration or severity of osteoporotic disease with the physical. soc ial and psyc hological parameters normally assoc iated with quality of life. For example, Cook et al. ( 1993) observed that the severity of discomfort was unrelated to the severity of vertebral fractu re, and the duration of the di sease d id not correlate with variables other than changes in lei sure and soc ial activities. l1lercfore. phannacoeconomic analyses have focussed on hip fracture, which may have a major effect on cost and/or compliance. The effects of venebral fracture and wrist frac ture o n quality of life have not yet been appraised.
Several in vestigators have considered qualityof-life alterations associated with menopause and HRT; however, most used assumptions that have not been verified by clin ical data. We instein ( 1980) assumed that hip fracture would result in disability equivalent to a utility loss of 0.05 per year of remaining l ife, and that endo metrial carcinoma would reduce quality of life by 1.0 quality-adjusted life year (QALY) in the remaining lifespan (excl uding theeffectofmona lity). An updaled analysis (Weinstein & Schiff 1983) assumed that nonfatal hip fraclure r es ulted in utility loss of 0. 1 per year of remaining life, and that endometrial carcinoma would result in utility l oss of 0.2 for an average of 5 years. These adjustments recogn ised that the extent to which hip frac ture affects quality of life was prePharmaco£conomics 5 (6) 1994 viously underestimated, and that endometrial carcinoma is a relatively sh ort-lived illness with a good survival rate. Cheung and Wren ( 1 992) also used these adjusted values in their pharmacoeconom ic analysis. and further assigned a utility loss for myocardial infarctio n equivalent to that of hip frac lU re.
Other phannacoeconomic analyses have attempted to evaluate the changes in quality of life that occur with different o utcomes and thus introduce more realistic assessments of the conseq uences of HRT. Tosleson and Weinstein (1990) differentiated between utili ty c hanges assumed to occur wi th various outcomes following hip fracture. For example, utility loss (quality weight) in the fi rst year following uncomplicated hip frac ture was estimated at 0.95. disabl ing hi p f r acture was estimated as 0.76. and hip fracture that required nursing home placement was valued as 0.36. Utility values as· signed to l ong term d isability and reside nce in a nursing home were 0.8 and 0.4. respectively.
Pharmacoeconomic Appraisal of HRT
Prevention of osteoporosis with HRT requi res long term admi nistration, with some investigators suggesting that a si gnificant reduction in the risk of fractu re is unlikely to occur for 15 to 20 years (Ge nant et al. 1989; Pitt & Brazier 1990) . Costs incurred over this period must be discounted so that their present value to the payer is taken into consideration (Katz & Welch 1993) . Cost savi ngs achieved over 20 to 30 years must be considerable to remain as a net saving if costs are discounted at a rate of 5% per year. As most of the benefits of fracture preven tio n do nOl manifest for an extended period. appropriate d iscounting is an important part of economic evaluations of HRT, and most studies discussed in this review have used constanHate discounting at 5%. In addition, the risks of endometrial or breast cancer, and the added benefits of reduced cardiovascular and cerebrovascul ardisease must be appraised in pharmacocconomic analyses of HRT.
As di scussed in section 5.2, com pliance is a particu larconcem in pharmacoeconomic analyses.
Acquisition costs of HRT and costs of screening cannot be offset if women fail to fill the prescription, or withdraw from therapy before it attains full effectiveness. Sensitivity analyses have an important role in testing different scenarios when definitive data concerning compliance are lacking.
The importance of sensitivity analysis is also clearly seen when uncertainties concerning the beneficial effect of HRT in the preven tion of myocardial infarction are considered. Some pharmacoeconomic stud ies have suggested that addition of progestogen (0 estrogen replacement therapy will reduce or reverse the cardioprotective effect of estrogen (Cheung & Wren 1992; Daly et al. 1992; Roche & Vessey 1990; Tosteson & Weinstein 1991) ; others have assumed that low-dose progestogen therapy might avoid this (Daly et al. 1992 ; Ti effen berg 1993a,b) . With sensitivity analyses, both scenarios can be tested to determine the influence of cardioprotection on the cost-effectiveness of HRT.
Cost-Benefit Appraisal
The cost-benefit of HRT prophylaxis for osteoporosis has been considered in 3 studies which differ substantially in design and cost components, and have therefore been discussed separately.
In a UK-based study Roche and Vessey (1990) used 3 hypothetical cohorts of I mi ll ion women on which to base their analyses: (a) women who had undergone hysterectomy and received oral conjugated estrogen 0.625mg daily for 15 years with 100% compliance; (b) women with intact uteri who received oral conjugated estrogen 0.625mg daily and lcvonorgestre l 0.075mg 10 days/cycle, also for 15 years with 100% compliance; (c) an untreated control group to which the current population morbidity and mortality rates were applied. These 3 hypothetical cohorts were followed from age 50 to 79 years. Costs were estimated using average inpatient duration of stay figures (based on 1985 data for England from the Hospital Inpatient Enquiry) and were discounted at 5% per annum, and risk rates were applied from identified epidemiological studies. The overall costs of 15 years of treatment were £ 1 37 for unopposed estrogen and £521 for com-539 bined therapy per woman, with savings of 19 000 and 7000 lives with each treatment strategy, respectively. Sensitiv ity analyses showed that 10 years of therapy gave only a modest reduction in costs (table VII ). In this analysis, risks for cardiovascular disease and stroke were assumed 10 reduce by 25 % for 5 years, and by 50% for 10 years of unopposed therapy; combined therapy was assumed to reduce these benefits by half. Treatment with unopposed estrogen resulted in 23 000 fewer deaths and 41 000 fewer hospital admissions, and combined therapy resulted in 12000 fewer deaths and 2 1 000 fewer admissions for card iovascular disease, although these risk reductions were smaller than those reported in epidemiological studies. Opposed and unopposed estrogen therapy both prevented approximately 2000 deaths and 22000 hospital admi ssions due to fractured neck of femur. The majority of savi ngs resulted from the reduced risk of stroke and cardiovascular disease.
In a l ess detailed study (Cummings et al. 1990b ), the average cost of a hip fracture in the US in 1984 was used to calcu late the economic effect of the expected increase in popu lation aged >50 years, up to the year 2040. These investigators also considered the effect of lifelong HRT started at age 50 years (assuming 50% reductions in both hip fracture and coronary disease mortality). The annual number of hip fractures among White women aged >50 years increased from 158000 in 1986, to 367000 in 2040. This was decreased to 275 000 and 18 3000 hip fraclU res in 2040 if 50 and 100% of women, respectively, received HRT. Assuming a 5 % annual inflation rate, total annual cost of hip fracture in the US would increase from $US7200 million in 1984, to $US240 000 million in 2040 if HRT was not given. Costs incurred or saved with HRT were not calculated. This projection was based on the agespecific incidence of hip fracture in each 5-year group remaining unaltered over the time period, unlike the actual incidence in Europe, which has increased in the past 30 years but is expected to plateau then dedine (section 1.1. 1). Funhermore, no allowance for increased life expectancy over the (and sav;ngs) of HRT per woman aged 50 years treated for 10 and 15 years, and followed unlil age 79 years . All costs were given in pounds sterling (£) and were discou nted at 5% per annum (Roche & Vessey 1990 " " Ischaemic heart disease treatment 1200 50-year period was made, and risks a nd ben efits other than hip fracture and myocardial infarc tion were not included. Clark and 5chuttinga (1992) evaluated a hypothetical cohort of 100000 White women in the US who were aged 50 years in 1 988. It was assumed that bone densitometry could be used to deli neate 3 risk groups, and t hat 90, 70 and 0% of wome n in the high-, medium-and low-risk groups, res pectively, elected to receive and conti nue with estrogen plus progestogen therapy for 15 years. Direct treatment costs of hip, vertebral and other fractures incl uded physician and outpatient costs, hospi talisation and nursing home care. Costs were discounted at the rate of 6%, and opportuni ty costs were modified to reflect an annual retu rn of 6% per year, with all costs and savi ngs adj usted to 1988 US dollars. Ind irect costs were incorporated by esti mating the value of lost productivity, which included reduced earni ngs from employ ment and homemaking services. It was assumed that fractures other than those of the vertebrae or hip occurred at an incidence and with risk rates similar to vertebral fractures, and that HRT reduced the risk of all fractures by 50%. Because vertebral fracture may be asymptomatic and therefore untreated, cost savings were apportioned to only 50% of the total nu mber estimated. Benefits of H RT ( i.e, fracture reduction) were assumed to begin after 5 years of therapy, and a total of 40 years follow-u p was incl uded in the study. It was unclear whether the benefits of HRT were assumed to cont inue after the cessation of treatmen t.
Prevention of vertebral fracture was greatest between 55 and 65 years of age, whereas hip frac tu res were most freque nt in women aged ~ 75 years . The cost of hip frac ture was substanti ally hi gher (4-and I O-fold) than that of vertebral or other frac ture. Red uced employment capacity with increasing age decreased the cost of treatment for all fractures; for example. hip fracture costs ranged from $US4 1 723 (age 50 to 54 years) to $US37 968 (age> 85 years) . The total cost of bone densitometry was estimated to be SUS 15 million, HRT costs were estimated as $U$42.9 mi llion, and the savings in medical costs and diminished income were $U563 million. Net savings for the 40-year period were t herefore assumed to be $US5.1 million. These estimates assumed 90% compliance in the high-risk group of women and 70% compliance in the medium-risk group (see also section 5.2). The break-even point (where savings offset the SUS l 5 million cost of screening) was ach ievable wit h treatment of only the hi gh-risk group if compliance was 77%, If both the med ium-and high-risk groups received treatment, the break-even point was attained if 70% of the h i gh-risk and 4 0% of t he medium-risk group were compliant with therapy.
This study did not consider any benefits or risks other than those for osteoporotic fracture. and dosage ... ariation and ad ... erse effects of therapy were not incorporated. Slack women were not included in the survey, as it was assumed that they were less susceptible to fracture than White women. Despite these shortcomings. this study is one of the few analyses to estimate indirect costs and is therefore a benchmark for futu re e ... aluations. ). The most comprehensi ... e of these was conducted in the U K and included fractured neck of fe mur, wrist and ... ertebral fracture. endometrial and breast cancer. and cerebro ... ascular and ischaem ic heart disease as disease end·points, as well as the risk of undergoing hysterectomy. or dilatation and curettage (Daly et al. 1992) .
Data from the UK ge neral population were used as a hypothe tical contro l group. and it was assumed that all women in England and Wales r ecei ... ed treatment for 10 years s t arting at age 50. Women who had undergone hysterectomy received estrogen only. while women with intact uteri were assumed to recei ... e either estrogen monotherapy o r estrogen plu s progestogen . Baseline treatment durarion was 10 years, and sensiti ... ity analyses examined the effects of treatment fo r 5 and 15 years. It was also assumed that women with intact uteri underwent endometrial biopsy e ... ery 2 years, and that all women were fu lly compliant with treatment. Daly et al. ( 1992) used a base mortal ity rate of25% for fractu red neck of femur but perfonned sensiti ... • ity analyses using different sets of publi shed agespecific case-fatality rates. Hospital costs were applied to t he annual difference in admissions between the treated and untreated groups and were therefore di scounled. The costs of pro ... iding healthcare dur-54 1 ing any period of prolonged lifetime following HRT use were calculated using a ... erage age-specific healthcare expenditure per capita figures.
For baseline analyses (table V I ), it was assumed that the rel at i ... e r isk of endometrial cancer i ncreased 6-fo ld fo llow ing 5 years of treatment in women with i nlact uteri recei ... ing estrogen only and decreased to normal le ... els 5 years after treatment was discontinued. The risk of breast cancer was assumed t o increase by 30 and 50% after 10 and 15 years of treatment. respecti ... ely, and t o r emain ele ... ated after treatment for a period at least as long as that of treatment. As in other studies, Daly et al. ( 1 992) assumed that the risk of fracture was reduced by 20% during the first 5 years of lTeatment, but by 60% thereafter. The reduction in ri sk was assumed to continue after the di scontinuation of treatment for a period at least as long as that of treatment. Similarly, a 25% reduction in the risk of coronary heart disease was estimated during the first 5 years of treatment. and a 5 0% r eduction following 10 years of treatment . with risk reduction afte r di scontinuation o f treatment equal to the Ireatment duration. The risk of cerebro ... ascular disease was assumed to decrease by 12% with estroge n and progestogen treatment. and by 25% with estrogen monotherapy. A 2-fold increase in the risk of hysterectomy or dilatation and curettage was assumed in estroge n rec ipients. and a 25% increased ri sk was assumed in combination therapy reci pients. Sensiti vi ty a nalyses were used to examine the effect of each di sease state on the costeffecti ... eness of treatment (table VIII ) .
Results indicated HRT was most cost effecti ... e (discounted cost per YLS :$; (3000) in women wi th hysterectomy (table VIII ), particu larl y o ... er longer tr eatment dural ions and when a reduc tion in cardio ... ascular risk was assumed. Combined estrogen and progestogen HRT was most cost effecti ... e fo r symptomatic women with intact uteri who received long term therapy (O!: 10 years). All treatment strategies showed a d ecrease in mortality and increase in discounted YLS per woman using baseline assumptions: 7% fewe r deaths and 0.25 YLS in women with hysterectomy. 5% and 0.1 1 YLS for women with intact uteri receiving estrogen only, and 3% reduclion in mortalit y and 0.19 YLS i n women receiving estrogen plus progestogen. Treatment for 15 years increased YLS per woman to 0.57, 0.45, and 0.25 for each of the above treatment groups, respectively.
Ischaemic heart disease had a s ubstantial influence on cost effectiveness. In women who had undergone hysterectomy, undiscounted YLS varied from 0.02 to 1. 17 for worst and best fisk scenarios, res pectively. Drug and monitoring costs also had a significant impact. An assumed 50% increase in es- Ph(lrmacoEconomics 5 (6) 1994 trogen plus progestogen acqui sition costs (fro m £48 to (72) increased the discounted cost per YLS from £ 14 400 to £19 900. Similarly. for women with inlact uteri receivi ng estrogen only, ann ual rather than biennual endometrial biopsy would increase the cost per YLS from £8300 to £ 11 100.
These general find ings were supported by those of an Australian study (Cheung & Wren 1992) benefits varied. Cheung and Wren (1992) used the population of women aged 50 years in New South Wales, and followed them throughout their remaining lifespan assuming e i ther no treatment, estrogen only, or estrogen and progestogen therapy. Unlike Daly et al. (1992) , who used only one preparation of conjugated estrogen on wh ich to base drug costs, these investigators used the average price of several different oral formulat ions. In addition, vertebral fracture was not included in the analyses. Nonetheless, Cheung and Wren (1992) found that both drug costs and cardiovascular risk had a notable influence on cost effectiveness, substantiating the fin dings of Daly et al. ( 1992) . Without the benefit of reduced cardiovascular risk, HRT in asymptomatic women was less cost-effective. With 5 and 15 years of estrogen plus progestogen therapy costs per YLS were $A780 and $AI71 8, respectively (table I X) . Weinstein and Tosteson ( 1990) updated anal yses in previous studies to reflect more recent epidem iological data concerning risks and benefits. They determi ned that 5 years of estrogen therapy produced a net life expectancy gain of 22 days, based on baseli ne assu mptions, whereas 5 and IS years of estrogen and progestogen therapy added 33 and 94 days to expected lifespan (table IX ) . Neither vertebral nor wrist fractures were included in the costs, and, more importantl y, any cardiovascular be nefi t was excluded from the analysis.
The esti mated gains i n li fe expectancy for HRT were modest; the cost per YLS (and therefore cost effecti veness) varied greatly with the assumptions and cost components included in each analysis. Assumptions o f 100% compl iance, wh ich w ere used for baseline scenarios in most analyses, are not appl icable i n the light of clinical studies on patient altitudes and compliance (section 5.2; Whittington & Fau lds 1994). Treatment of all postmenopausal women is similarly not feasible, although th is assumption was made in most studies . Resu lts in all studies were sensitive to quality of life, which ty picall y improves cost effectiveness (section 5.3; Whittington & Faulds 1994).
Comparison with Nonho rmonal Treatmelll
Rovira and Trin xet ( 1 993) performed a costeffectiveness study that compared sy mptomatic treatment usi ng veral ipride with the use of transdermal estradiol plus oral cyclic progestogens. Using a Monte-Carlo simulation of decision analysis including femora l, vertebral and wrist fracture, myocardial i nfarction and cerebrovascular disease, and breast and endometrial cancer as probable outco mes, they determined the cost effecti veness of 5 years of therapy. The total discou nted cost per patient was Pta576 ()()() for HRT ( 1 989 Spanish pesetas), with a life ex pectancy of 80.7 3 years. In comparison, veralipri de treatment cost Ptal 80 ()()() per patient , with a li fe expectancy of 80.54 years. The incremental cost-effecti veness of HRT was determined as Pta2.22 million per YLS f or baseli ne analysis, but varied from Pta 1.0 million to Pta7.5 million per YLS with sensitivity analyses.
In addition (Q its comparative design, this study differs from those described above in that compliance with HRT was reduced by 5% in each successive year of treatment over the first 5 years of therapy.
COSl EffeCliveneu of BOlle Milleral Density Sc reening
Assessing bone mi neral densi ty in postmenopausal women, then targeti ng HRT at those most al risk of osteoporotic fra ct ure, may be one means of improving cost effec ti veness. Tosteson et al. (1990) compared no intervention, universal trealment, and un iversal screeni ng plus treatment for several different bone mineral density thresholds. Screen ing was assumed to be based on dual-photon absorptiometry measurements at the hip, and asymptomatic White women were followed from 50 to I ()() years of age using a computer simulation model . The model used a set of transitional probabili ties to move the hypothetical cohort to and from health stales that reOected the prognosis, current morbidity and COS I of specific events: for example, uncomplicated hip fracture, dealh from hip fracture or placement in a nursing home. Health states were manipulated on a year-by-year basis, and each was allocated an annual cost. Cost-effectiveness rat ios were defi ned as fo llows: Baseline analysis assumed full compliance with a IS-year course of oral conjugated estrogen plus cyclic progestogen and did not consider any risks or benefits other than a reduction in hip fracture
PharmacoEconornics 5 (6) /994 and associated sequelae. The Tale of bone l oss was assumed to be the same in all women, and no bone loss was assu med with therapy. Tosteson e t al. (1990) found that therapy for women in the highrisk group (bone mineral density < 0.9 glcm 2 ) cost SUS II 700 per YLS, compared with $US68900 per YLS for uni versal treatment for 15 years. In conlrast, the incremeOlal cost-effectiveness for universaltreatment was calculated as $US349 000 per YLS, with no other risks and benefits considered. However, if the average di scounted lifetime savings for ischaemic heart disease exceeded SUS 1370 Daly et al. 1990 (1992)b Tosteson (1993) "" c Relative risk cited is for estrogen monotherapy; relative ris k for estrogen plus progestogen = 0.75.
d Relative risk in women with intact uteri currently using unopposed estrogen ~ 2.0; relative risk in women with intact uteri cu rre ntl y using estrogen plus progestogen = 1,25; these risk rates were not age·specific.
e Values are for women 1) with and 2) w~hoot a ut erus.
Values are from epidemiologica l studies consistent with the computer model used. which assumed no bone loss. or SUS 1535 for risk reductions of 25 or 57%, universal treat ment became more cost effective than screening pl us treatment. These r esu lts indi rectly support finding s by Daly et al. (1992) concerning t he importance of benefi ts on i sch aemic hean disease with HRT. The costs per YLS are al so markedly simil ar to those identified by Rovira a nd Tr inxet (1993) , despite the lack of discounting and different baseline assumptions. Rovira and Trinxet ( 1993) observed that cost per YLS fo r their baseline hypotheses was Pta2.22 mill ion (1989 Spanish pesetas); conversion of costs from Tosteson et al. ( 1990) s howed that treatment of women with bone mineral density <0.9 glcm 1 cost Ptal.72 million per YLS, and therapy for women in the mid-risk group cost Pta3.26 mill ion per YLS . Uni versal t reatment was est imated t o cost Pta5l.46 mi llion per YLS.
Cost-Util ity Appraisal
Whereas cost effectiveness is defi ned as the ratio of the net inc rease in healthcare costs to the net effective ness in terms of inc reased li fe expectancy. cost util ity is the same ratio adjusted for quality of li fe (Freund & Dittus 1992) . Therefore, many cost-effectiveness studies have been extended to include cost-utility outcomes. Most of the available data relate to c hanges in quality of life wi th relief of menopausal symptoms ( see Whittington & Faulds 1994) . This secti on focuses on qualityof-li fe changes and cost adjustments due to factors other than menopausal symptomatology.
Wein stei n ( 1 980) assumed that hip fracture resulted in a l oss of 0.05 QALY for each re maini ng year of life. and that endometrial cancer reduced the remai ning lifespan by 1.0 QALY. It was concluded that quality of life was of para mount importance in determining cost effectiveness. but that changes in utility weight due to sequelae other than menopausal symptom reli ef were of litt le importance (approx imately 5% of the fi nal utility value). Larger utility adjustments were assigned to hip fracture and endome trial cancer in updated analyses (Wein stein & Schiff 1983; Weinstei n & Tosteson 1990), which resulted in an additional 33 days of 545 quality-adjusted life expectancy (QALE) in women receivi ng 5 years of unopposed estrogen therapy. Estrogen and progestogen therapy for 5 years resulted in 37 additional days QALE (because of the reduced risk of e ndometrial cancer), and 15 years of this therapy added 10 1 days (Weinstein & Tosteson 1 990). These investigators determined the cost per QALY gained in asymptomatic patients was susn 000. compared wi th SUS33 100 for 0.5% gain and SUS 12 600 for 2% gain in quality of life for symptomatic patients receiving unopposed estrogen for 5 years; if no adverse effects due 10 progestogen were assumed, costs per QALY ga ined with combined estrogen and progestogen therapy were $US26 000, SUS 16 700 and $US8000, respectively (Weinstei n & Tosteson 1990).
Cheung a nd Wren ( 1992) also determined the change in QALYs wi th HRT, using uti lity weights to reflect emotional suf fering and disabili ty after hip fracture or myocardial infarc tion, and the adverse effects of progestogens. With a relat ive risk of death from myocardi al infarction of 0.5 and a n esti mated reduction in wrist and hip fracture incidence of 20 to 60%, 15 years of treatme nt with HRT in sy mptomatic women resulted in a cost per QALY of < SA I 0 ()(X). but progestogen-induced adverse effects rai sed the cost per QALY to SA I4 300. Shon term (5-year) treatment was not cost effecti ve compared with no HRT in asymptomatic women (cost per QALY $A44 800 to SA 158 000 depending o n tr eatment strategy), and long term ( IS -year) combined estroge n and progestogen therapy was only moderately cost effective (cost per QALY $A 17300 to $A45 8(0). These conclusions cannot be considered defin itive, as the utility weights were not based on clinical data, nor were utility weights apportioned to cerebrovascular disease or breast cancer. In addition. outcomes from hip fracture were assumed to be the same for all women .
This last concern was partially addressed in a study that foc used on HRT and the prevention of osteoporotic hip fracture. Tosteson et a l. ( J 990) adjusted cost-effectiveness data with utility weights reflecting the possible changes in quality of life that occurred with different o utcomes of hip fracture. For example, the utility weight for disability after hi p fracture was 0.8, compared with 0.4 for long t erm nursing home stay. After addi tional calcu lation for the probabi lity o f each seque la, all treatment strategies appeared morc cost ef fective. The incremental cost-effectiveness ratios for trealment of high-risk women or universal (r ealmenl were SUS II 700 and $US349 000, respectively, per life year gained; when adjusted for util ity weights these became $U542OO and $U$ I44 000 per QALY. Therapies fo r medi um-and low-risk groups were similarly affected, reduci ng to approximate ly 40% of unadjusted values. Allhaugh this study indirect ly considered adverse effec ts of therapy while discussing the effect of compliance on economic outcomes, the effects of other quality-of-life changes were not incl uded in the analysis. In a lat er re port, however, data were updated to include quality-oflife changes with menopausal symptoms. In 1992 US dollars. the cost per QALY in asymptomatic women with intact uteri receiving combi ned estroge n plus progestogen ranged from $US 17900 to $US32 000, assuming no adverse effects from therapy. In symptomatic women with no side effects, the cost per QALY was reduced to between $US9700 and $US 13000, depending upon the assumptions made concerni ng risk factors (Tosteson 1993) .
Pharmacoeconomic Status of HRT
Although the rev iew of the p harmacoeconomic status of HRT has been divided into short and long term therapy goals, in reality both the treatment of menopausal sym pto ms and the prophylactic effects on osteoporosis and heart disease must b e considered together. In Whittington and Faulds (1994) it was concluded that HRT was both medically a nd economically justified in women with severe menopausal symptoms. The effectiveness of estrogen-based hormone replacement therapy (HRT) in ameliorating menopausal symptoms was well established, and comparative trials indicated that oral conj ugated estrogens 0.625mg, oral ethinyl estradiol 0.02mg and transdermal estradiol PharmacoEconomics 5 (6) /994 0.05 mg have equivalent efficacy in relief of mi ld to moderate menopausal symptoms. Compliance was recognised as an important facto r in determi ning economic benefit in women with less severe symptoms.
The data concerning the effect of HRT o n quality of life were limited, but it was concluded that uti lity values used in pharmacoeconomic analyses may have underestimated the impact of me nopausal symptoms on q uali ty of life. Preliminary cost-benefit and cost-effectiveness studies suggested that conjugated estrogens and t ransdermal estradiol compared well with alternative therapies such as veralipride and Chinese medicines. Costuti li ty data indicated that the change in qua lityadj usted life years (QALYs) with H RT was always positive in symptomatic women, bUl the degree of change was determined by the baseline assumptions. Estimated changes in QALYs with HRT ranged from 0.006 for 5 years of treatment wi th unopposed estrogen in women with intact uteri, to 0.5 for 10 years of the same treatment in women with severe menopausal symptoms following hysterectomy.
A comparison of costs per QALY for diffe rent health interventions gives an indi cat ion of their probable value to society. Cheung and Wren (1992) assessed the cost effectiveness of HRT in comparison with other health interventions: for example, coronary artery bypass surgery ra nged from $A8 140 to $A 17 900 per QALY, and treatment of hypertension ranged from $A18 500 to $A37 600 per QALY. compared with $A65 10 to $A64 800 fo r HRT. Similar comparisons of cost per QA LY have been performed with other health inte rventions, and HRT is generally ranked i n the midrange of cost per QALY values ci ted. For example, cost per QALY fo r hospital haemodialysis was determined as $US54 000, oral HRT was $U527 000, and neonatal intensive care was $U54500 (Rovira & Tri nxet 1993) . Other investigators have determined the comparative cost per QALY of HRT in selected groups of women (Daly et al. 1992;  fig. 2 ). HRT intervention compared favourab ly w i th other health interventions in common use in older adult popUlations. It is unknown whether the same meth-ods for determining cost per QALY were used in each estimate, and therefore whether these data are trul y comparable.
The definitive phannacoeconomic status of HRT is thus difficult to detennine, with numerous variables to consider and further evidence required in many therapeutic aspects.
1 General Prescribing Considerations
HRT is best initiated at the climacteric, before appreciable bone loss has occurred. Current clinical data support its s tatus a s the therapy of choice in many countries f or the alleviation of menopausal symptoms and urogenital estrogen deficiency (Whittington & Faulds 1994) , and the prevention of oSleoporosis. HRT has al so been recently accepted in some countri es as prophy laxi s in the prevention of ischaemic heart disease in postmenopausal women . Cardiovascu lar disease is the most common cause of death in developed countries, and the beneficial effects of HRT on cardiovascular health are a major prescribing consideration.
Limited data suggest HRT may also be suitable for the treatme nt o f established osteoporosis (Lufkin et al. 1992 ), but furt her long term studies are required to confirm this. Long term clinical data concerning the prophylactic role of HRT in t he 547 prevention of fracture are conflicting. and although it seems likely that treatment for ~ 10 years will maintain bone density and thus r educe fracture incidence, definitive ev idence is l acking. Most pharmacoeconomic analyses have assumed this benefit to be fact, and have further estimated a waning effect of HRT that persists for a period equal to that of the treatment duration. All pharmacoeconomic studies have assumed thai the optimum period to commence HRT is at the menopause (and have based studies from this time onward), but few have considered continu ing HRT for the entire remaining lifespan. Clinical data concerning the effects of osteoporotic frac ture o n quality of life are also insufficie nt for a complete evaluation of cost-utility.
In women with intact uteri, the risk of endometrial cancer usuall y precludes the use of unopposed estrogen, despite some evidence that thi s therapeutic regimen remain s cost-effective. Costs of HRT treatment depend in part on the degree of monitoring considered necessary, and this differs considerably between countries. Routine endometrial biopsy may not be necessary with the use of HRT containing estrogen plus progestogen , and thi s may reduce monitoring costs 10 acceptable levels. The need for annual mammography is not supported b y current epidemiological dala conb """' " ""'''''''''''=''"' cerning the r isk of breast cancer with HRT, although l o ng te rm prospective evidence is required to confirm this conclusion. Some countries have screening programmes for breast cancer in place. and therefore there is no additional r equire ment for this monitoring.
Al though the ri sk of osteo poros is is gre aler in Caucasian or Asian women, and in women wi th additional ri sk factors s uch as a sedentary lifestyle. rheumatoid arthritis. smoking. or heavy alcohol intake (table I), these risk factors cannot be used as a direct means of determining risk in individual women. Screening procedures appear the most effecti ve no ninvasive means o f identifying aI-ri sk patie nts and for monitoring bone mineral d ensity. Additionally, adequate exercise, dietary calcium intake, cessatio n of smo king, and measures to prevent fa lling a re recommended lifes tyle changes for all postme nopausal wo me n.
Compliance with the rapy, partic ul arl y in the lo ng term , is a n important issue that has been inadequately addressed in clinical studies and only partially evaluated in phannacoeconomic analyses. Clinical d ata a re avail able o nly for periods up to I year: however. it seems long term compliance is likely to be low, perhaps i n the orde r of 30% (Anon. 1992). Adequate and accurate information concern ing the benefits and risks of HRT for both clinicians and patients may improve compli ance. as studies suggest that most patient information comes from media sources, but that acceptance of HRT is high when therapy has been r ecommended by a doctor (Whittington & Faulds 1994) .
To improve compliance. the t ypeofHRT formulation and the dosages given must be tailored t o the individual p at ient For example, the higher acquisition costs of transdermal HRT may be offset by increased compliance. particularly with newer tranSdermal pre para tions t hat include lo w dose progestogcns in the delivery system. and thus preclude the need t o take oral agents. At present, however, a ltho ugh comparative effi cacy for most f ormulatio ns is well established. studies comparing lo ng te rm compliance between formul ations have yet to be performed.
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Formulary Consideratio ns
Formulary decisions concern ing the use ofHRT for prevention of osteoporosis and ischae mic heart disease sho uld conside r which wo men would deri ve the most benefit, the optimum treatment duration and dosage, the need for screening programmes and the reliability of the phannacoeconomic evidence.
Se lecti ve therapy a ppears to be more cost e ffective than universal treatment. Women wi th severe menopausal symptoms. particularly those who have undergone hysterectomy, are the most eli gible candidates fo r HRT, as are those at high risk of osteoporotic fracture ( usually wo men having bone mineral density 2 sta ndard deviations below average) or cardiovascular d isease. Due t o t he conflicting evidence to date, women at risk of breast cancer need t o be considered f or HRT based o n the ir individual r isk profiles and prefere nces for treatment. Further research i s r equired to clarify the ro le o f HRT in women with rhe umatoid arthriti s o r wilh previously treated breast cancer, although initial reports s uggest these populations may benefit. Optimum treatment duration appears to be 2: 15 years, commencing at m enopause and continu ing for the remaining lifespan. Current users of HRT with more than 15 years of prior HRT had a 40% reductio n in mortali ty compared with non-users (He nde rson et al. 199 1). Gorsky el al. ( 1994) calculated a gain of 395 1 QALYs in a coho rt of 10 000 women taking estrogen for 25 years. However. t herapy for ~ 10 years may also be cost effective compared with no HRT.
There is still much controversy over the widespread use of bone minera l d ensity screening in postmeno pausal women (Raffi e 1993). Cost-benefi t and cost-effectiveness studies suggest, however. that screening and subsequent treatment of highand m oderate-ri sk g roups is econo mically benefi cial . particul arl y with hi gh (> 70%) levels of compliance with HRT. Clinical data from women advised t o commence HRT due to hi gh risk offracture s uggest that initial compliance may approx imate 75%. but this may reduce to S 60% after 6 mo nths (Ryan et al. 1992b ). Long term compliance data are unavailable. but evidence suggests that phar-HRT: A Pharmacoeoonomic Appraisal (II) macoeconomic data may overestimate the benefits of widespread screening. As the i nitial outlay for a bone mineral density screening programme is s u bstantial, the expected b enefi ts must be evaluated carefully. Additionally, as many of the benefi ts of HRT are extraskeletal, it m ay be inappropriate to screen women using on ly skeletal p aramet ers. To date, however, there are no pharmacoeconomic or clinical data concerning screening fo r women with high cardiovascu lar risk and subseq uent treatment with HRT. This is an important area for futu re research.
To assess the accuracy and validity of pharmacoeconomic evaluations, the assumptions of risks and benefils, compliance levels, and utility changes used in the a n alyses must be compared with clinical evidence. Many of the assumptions concerning risks and benefits made in the p harmacoeconomic analyses are not supported by current clinical data. For example, the optimal duralion of therapy with regard to cardioprotection is u ndecided, as most evidence stems from studies in women who had u sed estrogen, compared with women who had n ever used estrogen. Some evidence suggests that relative risk of cardiovascular disease decreases wi th therapy duration (Henderson et a l. 1991) , but supporti ng data are required. Data concerning t he c hange in re lati ve risk after wi thdrawa l of the rapy are also lacking. Assumptions of relative risk of cerebrovascular disease in pharmacoeconomic studies have varied between 0.5 and 1 .0; lar ge clinical trial and meta-analysis estimates of relati ve risk vary between 0.69 and 0.96.
Pooled relative risk f or hi p frac tu re with HRT was 0.75 according to data from II e pidemiological studies, with therapy for <:!: 10 years reducing the relative risk to 0.5. This is s im ilar to risk rates assumed in pharmacoeconomic studies, although some studies may have slightly overesti mated the benefi ts of long term HRT by using a relative risk rate of 0.4. Risks of endometri al and br east cancer varied considerably between studies and may have been overestimated in many i nstances. Compliance levels were us ually overestimated and utility values underesti mated in pharmacoeconomic analyses.
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Despite i nadequate data and conflicting r esults in some t he r apeutic areas, certain conclusions are possible regarding the pharmacoeconomic benefits of HRT on longer t erm sequelae of m en opause. HRT is both medically and economically benefi cial in women wi th a high risk of osteoporotic f ractu re. The effect of osteoporotic fractures on the health and well-being of an individual will diffe r depending on p at ient age and baseline health status, as well as the type and degree of severi ty of the fracture. In women with a moderate r isk of fr acture, HRT is al so economi ca ll y beneficial if comp liance is good. Added benefit s o n m enopau sal symptoms, urogenital estrogen d efi ciency (W hittington & Faulds 1994) and cardiovascular outcomes, the level of monitoring t hat accompanies therapy. and the acquis it ion cost of the rapy w ill markedl y affect the cost effectiveness. As discussed in Pan I, most pharmacoeconomic studies in asymptomatic women do not support widespread use of HRT, unless the duration of therapy is prolonged. However, in wome n with severe symptoms HRT is cost effective, even for shon term therapy that has lillie effec t on osteoporotic bone loss.
In conclusion. al though many fac tors influence its economic viabi lity, HRT i s medicall y and economically beneficial i n women with severe menopausal symptoms and in wome n with high risk of osteoporotic fracture. The cardioprotection afforded by HRT adds a signi fi cant benefit which enhances cost effectiveness.
